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initial goutpresentation are acutepain, swelling, erythema and tenderness inperipheral
jointsbuteventuallyunremittingarthritis,jointdeformityandtophusdepositionmaydevelop
with long ?standing hyperuricaemia. Patients with gout suffer not only arthritis but also
cardiovascular,renal,metabolicandothercomorbidities.Sincegout istheconsequenceof




Health Insurance Database in Taiwan, both of which are representative of the general
populationinthesetwocountries.Sixdifferentanalyseswerecarriedout:(1)epidemiology
ofgout in theUK (chapter3); (2)epidemiologyofgout inTaiwan (chapter4); (3)Nature
history of gout following diagnosis in the UK (chapter 5); (4) familial aggregation and






2010)than intheUK(1.77per1,000personyears in2012).Theprevalenceand incidence
wereincreasingintheUKinthepastdecade,however,bothofwhichremainedstableinthe
period2005 ?2010inTaiwan.Comparedwiththegeneralpopulation,individualswithafamily
historyofgouthada two ?fold increased riskof thedisease.The relative contributionsof
heritability,sharedandnon ?sharedenvironmentalfactorstoexplainphenotypicvarianceof
gout were 35.1%, 28.1% and 36.8% in men and 17.0%, 18.5% and 64.5% in women,
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Gout is the most common inflammatory joint diseases with a wide range of clinical
manifestations.Itisacrystaldepositiondiseasethatresultsfromformationofsodiumurate
crystalswithin and around peripheral joints.(Choi et al., 2005b) Chronic hyperuricaemia,
resulting from inefficient renal excretion or excess production of uric acid, is the key
predisposing factor.Clinically,gout ischaracterizedbyrecurrentacuteattacksofarthritis,
chronic inflammatory and mechanical joint symptoms, subcutaneous urate crystal
concretions(tophi),uratenephropathyandurolithiasis.(Wortmann,2006)Althoughchronic
hyperuricaemiaiscentraltogoutitdoesnotinevitablycausethedisease,butmanystudies
have reported an increase in prevalence both of hyperuricaemia and gout.(Currie, 1979,
Harrisetal.,1995,Klempetal.,1997)
Goutisnotonlyadiseaseofjoints.Italsoassociateswithmanydisorderswhichmayaffect











comorbidities andmortality of gout using two national administrative databases: theUK
Clinical Practice Data ?Link (CPRD) and the Taiwan National Health Insurance Research
Database(NHIRD).









Gout isadiseaseofantiquity,asdemonstratedby fossilevidenceofgout inacastof the




















the cause of gout and describe tophi as local concentrations of humours.(Porter and
Rousseau,1998)
Theword"gout"(derivedfrom"gutta"whichmeans'drop")wascoinedtodescribepodagra




the clinical features and associations of gout we currently acknowledge; for example,








clearly described the symptoms of gout and suggested treating it by "strengthening
circulation by improving kidney". Several terms were used to describe gout in Chinese
medicine,suchas"white ?tigerwindpain"and"joint ?runningwind.Morerecently,gout is
termed"tongfeng"whichliterallymeanspain(tong)andwind(feng).Thistermwascoined
by ZhuDanXi (1281 ?1358)whowrote in "Further treatiseson thepropertiesof things   ?
Treatiseongout":




















and then biopsied the site to confirm historical evidence of an inflammatory response.
FreudweilerlaterdemonstratedthatMSUcrystalscausebothinflammationandnecrosisby






Faires andMcCarty in Philadelphia independently produced similar results at the same









byWilhelmHis Jr., Seegmiller andMcCarty) ofmonosodium urate (MSU) crystals as the
aetiological agent in gout was gout established as a distinct crystal deposition disease.
Nowadays,goutisrecognisedtohavearangeofphenotypicexpressionandcharacteristics
which include:elevated serumurate concentration (hyperuricaemia); recurrentattacksof
acute arthritis inwhichmonosodiumMSU crystals canbedemonstrated in synovial fluid
(figure1.1a);compactedaggregatesofMSUcrystals(tophi;figure1.1b)depositedchieflyin
and around joints,which sometimes lead to joint damage and deformity; renal disease






























1989) However, a comparatively lower sensitivity and inconsistency between different
observersinMSUidentificationreducesthecertaintyofrulingoutgoutinpatientswithout







the most common first affected joint (figure 1.2). Other typical characteristics include
swelling, severe pain that reaches itsmaximumwithin 12 ?24 hours,marked tenderness,







































criteria cannotbeapplieddue to insufficient clinicaland laboratory information. In such situations, the




The utility and validity of gout diagnoses specifically within insurance claims data has also been
assessed.(Harrold et al., 2007, Singh et al., 2007)Harrold et al. demonstrated that a diagnosis of gout
recordedon2ormoreoccasionshadapositivepredictivevalueof61%.(Harroldetal.,2007)Anotherstudy








may present with pain, swelling, redness and loss of function, which are all typical features of an
inflammatory arthritis. The first attack of gouty arthritis is usually in small joints of the lower limb, in
particularthe firstMTP joint (podagra).Foratypicalgoutattack,maximal inflammationusuallyoccurs
within4to12hoursafteronsetandtheintensityreducesgraduallytospontaneousresolutionevenwithout
treatment.Constitutionalsymptomssuchasfevermayalsomanifestinsevereattacks.
Generally,amono ?articularonset ischaracteristic in70%to90%ofaffected individualsandpolyarticular
attacksoccurin11%to28%ofpatients.(NishiokaandMikanagi,1980,Lawryetal.,1988)InthreeUKseries,
thejointsinvolvedmostcommonlyindescendingorderoffrequencyarethefirstMTPjoint,ankle/foot,knee
and thenother joints.(Grahame and Scott, 1970,Currie, 1978,Roddy et al., 2007a)A smallnumberof
patientsmaypresentwithextra ?articularmanifestations,suchasbursitisordischargingsubcutaneoustophi.
Tophigenerallyarewhitetoyellowsoftorfirmlumpsundertheskin(figure1 ?3).Themostcommonsitesof












unremitting chronic polyarticular arthritis if not treated. Septic arthritis can occurwith explosive joint
inflammation,ofteninlargejoint.Butoncetreatedcompletely,itisthoughttobecured.Sometimespost ?
infectious arthritis can mimic gout. However, these kind of arthritis presents with a more modest
progression;patientsveryrarelytransitfromasymptomatictoacutearthritisinseveralhours.Othercrystal ?
inducedarthritis,suchasCPPDarthropathy,canalsomimicgout.However,crystal ?inducedarthritisother




Withevident tophus, thediagnosisofgout isalmostalwayscorrect.Rheumatoidnodules,oftenseen in
patientswithadvancedrheumatoidarthritis,alsopresentwithsubcutaneousnodules.However,rheumatoid
nodules are often rubbery firm and coldwithoutmarked inflammation. Tophus normally is hard but
sometimesitcanbesoftiftheuratecrystalsinsideliquefies.Severeinflammationcanbeseenwithtophus
but is very uncommon with rheumatoid nodules. Gout and rheumatoid arthritis tend to bemutually
exclusive; therefore the distinction between tophus and rheumatoid nodules can be obvious with














FIGURE1 ?5 TYPICALRADIOGRAPHIC FEATURESOF TOPHACEOUSDESTRUCTIVEARTHROPATHY (PERSONAL
COLLECTION;WITHPATIENTCONSENT).
The typical natural history of gout is generally considered to progress through the following phases: a
prolongedperiodofasymptomatichyperuricaemiaduringwhichMSUcrystalsarefirstformingandbuilding
in concentration; clinical presentationwith acute attacks; asymptomatic inter ?critical periods between







intervention.(DalbethandStamp,2014)This staging system incorporatesour recentunderstanding that
MSUcrystalsarealsopresentinpeoplewithoutanysymptomsandsigns.(Puigetal.,2008,Howardetal.,
2011,Pinedaetal.,2011,DeMigueletal.,2012)However, further study is stillneeded tovalidate this
system.
Thisnew staging systemmarks anew eraof goutunderstanding. Since the culpritof gout and golden
standard of gout diagnosis MSU crystal in synovial fluid can be identified in hyperuricaemic patients
withoutoutrightsymptoms,theso ?calledpatientswithasymptomatichyperuricaemiadonotseemtobe



















the differences in the definition of the condition, geographic locations, race andmethod and time of

















Racial and geographic differences appear to be significant. Early European studies, including the
Netherlands,(DeBlecourt,1954) France,(Zalokaretal.,1974) Finland,(IsomakiandTakkunen,1969)and
Denmark(DeMuckadellandGyntelberg,1976) indicatedagenerally lowprevalenceofgout.However,a
more recent study found a prevalence of 1.4% in Germany, using the IMS disease analyser,which is






Japan andChinabothhave a lowerprevalenceof gout than inneighbouring Taiwan.Anearly study in






prevalenceseemstobe increasingonthewhole. Ingeneralprevalenceofgoutwas lower inthestudies
conductedinthe1980scomparedtothoseconductedin1990s.Studiesconductedinthenewmillennium
oftenareofhighestprevalence.Since therewerenomajorchanges ingoutdefinitionandclassification
criteria (ACRcriteriawas released in1977),wecouldnotblame the increasingprevalenceon themore
inclusiveclassificationcriteria.Manystudiessuggestgoutispoorlymanagedandpatientadherenceisworst
ofallchronicdiseases.Thispatterndoesnotseemtochangesignificantly.Thereforeheightenedawareness





tohave thehighestprevalenceof gout in theworld.Aboriginals in Taiwan, cousinsofPolynesians and
Melaneciansalsohaveaveryhighprevalenceofgout.Incontrast,Caucasianshavelowerprevalenceofgout.





















studieswerebasedonself ?reportedgout,which isprone tobiasedestimatesdue to inconsistent recall.
Despitegout isrelativelyeasytodiagnose, identificationofgoutcasesdependonpatientswillingnessto
seekmedicaladvice,whichisnotoriouslypooringoutpatients.Secondly,thesamplingstrategiesarevaried
andnot consistent.Many studieshavedifferentage restrictions, therefore compromising comparability
acrossstudies.Further,somestudieswerebasedonhospitalorclinicrecordsofspecificinstitutions,which
could lead toaselectionbias formoreseverecases.Thirdly,sincegouthas longasymptomaticperiods,
definitionofobservationperiodcouldhavebiasedtheestimationofgoutepidemiology.Forinstance,Elliot


































10539 45+ Survey Self ?reported 4.33/ ?
(Steven,1992) 1987 Scottish
Highlands

















































































































period. Therefore, different observation periods in different physician ?based studiesmay
hinder comparability of these estimates. For survey based studies, estimates of gout
incidenceissubjecttothelengthofrecalloftherespondents.Patientswithremoteattacks
may thusbeing classifiedas incident cases, resulting inoverestimationofgout incidence.
Basedon theseconsiderations, theRochesterstudymaybe theonlystudy inwhich their








Theprimarydriving force forpredisposition toMSU formation ishyperuricaemia.Several





That hyperuricaemia is a genuine risk factor for gout which has been demonstrated
epidemiologically in both the Framingham study(Hall et al., 1967) and Normative Aging
study.(Campionetal.,1987)Acleardoseresponserelationshipexistsbetweenserumuric
acid(SUA)levelsandcumulativeincidenceofgout.Inaddition,intheNormativeAgingstudy
hyperuricaemia alone renders other predictors of gout, including age, bodymass index,








Klempetal.,1997)SUA levels in theUK(PopertandHewitt,1962)and inNorthAmerican
Caucasians(O'Sullivan, 1972) are similarwhereas USmixed racial studies demonstrate a
greaterprevalenceofhyperuricaemiainAfricanAmericansthanCaucasians.(Agamahetal.,





Early genetic studies of gout focused on rare monogenic disorders that cause marked
hyperuricaemia and premature gout, for example, deficiency of hypoxanthine ?guanine
phosphoribosyl transferase (Lesch ?Nyan syndrome), over ?activity of phosphoribosyl ?1 ?
pyrophosphate synthetase, and hereditary renal disease (familial hyperuricaemia
35
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Several European studies report rural residents to have lower risk of gout,(Isomaki and
Takkunen,1969,PopertandHewitt,1962)afindingalsosupportedbyastudyinTaiwanwhich
foundalowergoutprevalenceinrural(0.16%)thansuburbanandurbanareas(0.67).(Chou
etal.,1994)Areaswithhigher socioeconomic status seem tohavea lowerprevalenceof
gout.(Gardner et al., 1982) The UKmorbidity statistics from general practice (1970 ?71)













veterinariansaged40 to75yearsofage in1986.TheHPFSassesseddietary intakeusing
questions on 13 foods and beverages, (Rimm et al., 1992) to enquire about the diet of
enrolees.(Choietal.,2004b,Choietal.,2004a)
TheHPFSreportedarelativeriskof incidentgoutof1.41 for thehighestquintileofmeat
intakeand1.51forthosewiththehighestquintileofseafoodintake.Intriguingly,purine ?rich
vegetables did not result in an excess risk of gout.(Choi et al., 2004b) A dose response
relationshipwasfoundbetweenalcoholconsumptionandriskofgout.Choietal.reporta
relative risk of 1.71 for every 10g increase in daily alcohol consumption.Among various









lead ?inducedhyperuricaemia isnot clearbut low ?levelenvironmental leadexposuremay
accelerateprogressiverenalinsufficiencyandhencecausehyperuricaemia.(Linetal.,2003a)
An earlier study suggested that lead may predispose to MSU crystal deposition under














categories, particularly cardiovascular and renal diseases, can serve as risk factors and










Hyperuricaemia is the hallmark of gout. It is also a common component of metabolic
syndrome. Choi et al. reported a progressive increase in the prevalence of metabolic
syndromewith increasinguricacid levels.(ChoiandFord,2007)ArecentstudyfromKorea
foundtheprevalenceofmetabolicsyndromeamonggoutpatientstobealmost5timeshigher
than in controls.(Yoo et al., 2011) Choi et al. reported a 62.8% prevalence ofmetabolic
syndromeamonggoutpatients,comparedto25.4%incontrolsinthethirdNationalHealth















A recentmeta ?analysis, incorporating results from 18 prospective studieswith a total of
55,607participants,reportedthathyperuricaemiawasassociatedwithanadjustedrelative
risk of 1.41 for incident hypertension.(Grayson et al., 2011) However, recent trialswith
42
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febuxostat, a xanthine oxidase inhibitor, did not find beneficial blood pressure lowering
effectsdespitesignificanturateloweringeffects.(Beckeretal.,2010,Schumacheretal.,2008)
The association between gout and hypertension has long been observed.(Wallace, 1975,
Rapado,1974,Breckenridge,1966) In theNormativeAgingStudy,goutwas3 timesmore















increase in SUA levels.(Obermayr et al., 2008) In addition, hyperuricaemia is strongly
associated with CKD, independent of the presence or absence of the metabolic






(men: solid line;women: dashed line; figure adapted from Hyperuricaemia and













Uric acid crystalsmay deposit in the renal tubules and cause kidney stones. The risk of
common calcium containing stones is also increased in peoplewith hyperuricaemia. The
HealthProfessionalfollow ?upstudyfoundthatthediagnosisofgoutwasassociatedwitha
















The Framingham study found a 60% excess risk for coronary heart disease among gout
patients.(Abbottetal.,1988)Ahighriskofacutemyocardialinfarction(AMI)ingoutpatients







Whether SUA levels areneuro ?protectiveorneurotoxichas longbeendebated.A recent
cohort study found no significant association between SUA levels and ischemic stroke
outcomes.(Seetetal.,2010)However,ameta ?analysisfoundthathyperuricaemiaassociated
withasignificantlyhigherriskbothofstrokeincidence(relativerisk[RR],1.41)andmortality






A greater risk for incident heart failure was recently demonstrated in hyperuricaemic
patients.(Ekundayoetal.,2010,Krishnan,2009) Inaddition,higherSUAassociatedwitha
poorer prognosis in patients with systolic heart failure.(Wu et al., 2010) Whether
hyperuricaemiaisariskfactororabystanderbiomarkerisstillunderdebate.Whileearlier
studies suggested lowermortality inheart failurepatients receiving long ?termallopurinol
treatment,amorerecentstudyfoundnochangesinbrainnatriureticpeptide,leftventricular




































British Columbia LinkedHealthDatabase and PharmaCare data,DeVera et al. identified








investigated. Two recent studies, theMRFIT (Krishnan et al., 2008) and HPFS (Choi and
Curhan,2007) studies,both confined tomen, reportedexcess cardiovascularmortality in
peoplewithgout.Althougharecentstudyfoundwomenwithgouttohavearelativeriskof
1.39 for acutemyocardial infarction,(DeVera et al., 2010) the survival impactof gout in
womenisstilluncertain.
Kuoetal.reportedthatindividualswithahistoryofgouthaveahigherriskofdeathfromall
causes and from cardiovascular diseases, independent of age, sex, smoking, metabolic
syndromeandproteinuria.(Kuoetal.,2010a)Amorerecentstudyinvestigatedthemortality










inflammatory drugs (NSAIDs), corticosteroids (intra ?articular, intramuscular or oral) and
intramuscularadrenalcorticotrophinhormone(ACTH).(Terkeltaub,2010)Icepacksalsohelp
reducepainandinflammation.(Schlesingeretal.,2002)
For long ?termmanagement the treatmentpriority is to reduce SUA tobelow the critical
saturationpointatwhichcrystalsmayform,thuspreventingfurtherMSUcrystalformation
anddissolvingawayexistingcrystals.(Terkeltaub,2010)Onceallcrystalsare removed the
personwillhaveno furtherattacksand the riskof further jointdamagedue tocrystals is
removed. Thereare twocategoriesofeffectiveurate lowering therapy (ULT), specifically
xanthine oxidase inhibitors and uricosuric drugs.  The two xanthine oxidase inhibitors
allopurinolandfebuxostatarethemainULTstobeusedintheUK,thethreeuricosuricagents,




Acuteattacks frequentlyoccurafter initiationofULTpossiblydue topartialdissolutionof
MSU crystals which encourages their shedding from cartilage into the joint cavity.
Prophylactic therapywith regular low dose colchicine orNSAID for the first fewmonths
followinginitiationofULTmayreducetheriskofacuteattacks.Thisapproachiseffectivein





avoidanceofexcess intakeofalcohol (especiallybeer)and fructosecontainingbeverages.
Measurestokeepidealbodyweight,suchasdietarycaloricrestrictionandadequateexercise,
shouldbeencouraged.Liberalwaterconsumptionmayenhancerenalurateclearanceand
prevent calculi. Effective treatment of comorbid hypertension, insulin resistance and
dyslipidaemiaalsoincreasesrenalurateexcretionandreducesSUA.
















system. They record the "activities" incurredwhen enrolees seekmedical care, such as








dataareobtained ina"natural"environment, rather than in specialised settings soavoid






are limited to the population and medical services covered. Secondly, the accuracy,
completenessandclinicalinterpretationofdiagnosticcodesareoftenquestionable.Sincethe
diagnosis is often coded according to an existing scheme, such as the International
ClassificationofDiseases(ICD)systemortheReadsystem,rareornoveldiseasesmaynotbe
correctly classified. Many administrative databases are created to facilitate claims and
reimbursementbasedoncertaindiagnoses.Thereforethediagnosesmaybe influencedby
the financial incentive. As the data are enormous in most administrative databases,

























medications, risk measures, incidence and prevalence and methods of standardisation.
Specificmethodsaredescribedinrelevantchapters.
Chapter3reportstheuseoftheCPRDtoinvestigateprevalence,incidenceandmanagement
ofgout inprimarycare intheUK.Thisstudypresentsdetailedestimates in2012andalso
trendsofestimatesfrom1997to2012.
Chapter 4 reports the use of the NHIRD to study the epidemiology of gout and its
management inTaiwan from2005 to2010.This study reportsprevalence, incidenceand
managementofgoutinTaiwan.
Chapter 5 investigates the nature history of gout after the diagnosis of the disease and
estimatesthecumulativeprobabilityoffulfillingeligibilityforULT.






































The study of this thesis is jointly funded by two projects: Prediction of cardiovascular
outcomesamonggoutpatients:apopulationstudybasedontheNationalInsuranceResearch
Database and General Practice Research Database, which is sponsored by Chang Gung
Memorial Hospital (CGMH) and Construction of predictivemodel for prognosis of gout
patients:usingtheNationalHealthInsurancedatabaseandtheUKCPRDwhichissponsored
by the National Science Council (NSC) of Taiwan. The original protocols of the ethical












TheCPRDcovers thepopulationof theUK,with theprimarycarecomponentof thedata
previouslyrecognisedastheGeneralPracticeResearchDatabase(GPRD).However,currently









tests, immunisations, information on medical staffs, health promotion activities,
management andqualityoutcome framework indicators.Vision software is anelectronic
systemforgeneralpractitionerstomanagepatients,whichrecordsinformationprimarilyas





thedatawereconsideredacceptable forresearch following internalqualitycontrol.There
were5,119,066peopleregisteredintheCPRDin2010whofulfilledstandardqualitycriteria
(8.21%oftheUKpopulation).Over1.1billionrecordsofconsultationsfrom632practicesare
available.With such a large amount of patient data and good representation of theUK
population,theCPRDprovidesanexcellentopportunityforresearchinareassuchasclinical







includingHospitalEpisode Statistic (HES),CancerRegistry,Myocardial IschaemiaNational
AuditProject (MINAP),mother ?baby link,national jointregistry,socioeconomicstatusand




The structure of the CPRD is roughly divided into registration data, which records






































approval, investigators canobtain access tooriginalmedical records and contactGPs for
additional questionnaire surveys of enrolled individuals. The CPRD is a powerful tool to


















registration information and data on original claims for reimbursement, including






















































































































































Other data files are briefly discussed. GD and GO files contain details of prescriptions
dispensed atpharmacies.DT andCT files containmonthly summariesof ambulatory and
inpatientclaimsforeachmedicalfacility.Variousregistrationfiles(HOSB,HOSX,HOX,and
DETA)contain informationregardingsubspecialties,medicalservices,gradingandcontract





not included as these diseases do not qualify for a catastrophic illness certificate. The
72

catastrophic illnesses defined byNHI include cancers, congenital diseases and congenital
anomalies such as haemophilia, chronic kidney disease requiring renal replacement
treatment, systemic autoimmune disease, chronic psychiatric diseases,metabolic, those
receiving organ transplantation, paralytic syndromes, major trauma, respiratory failure
requiringmechanicalventilation, severemalnutritiondue toenterectomy,decompression
sickness, immunodeficiencies, several occupational diseases such as coal workers'


















In addition to three LHIDs, there are also packages of data retrieved from the original





TheNHIRDhas several strengths.As theNHI covers theentirepopulationofTaiwan, the
NHIRD is a genuine nationwide database and the information recorded in the database
reflectsrealworldpracticesinTaiwan.Withdataofmorethan27millionpeoplesince1996,
evenacohortofararediseasecanbeestablishedreadily.Also,diseasecharacteristicsare
based on physician diagnosis rather than patient self ?report, thus improving diagnostic
validity.
There are also limitations to the NHIRD. The anonymisation of personal and hospital
identificationmakes external linkage to other databases difficult, if not impossible. The
databaseisbasedonreimbursementfromtheNHI,thereforeitdoesnotcontainresultsof








andmost cited health research databases in theworld. They are representative of the
national populations of theUK and Taiwan.However, there are keydifferences that are
importantwheninterpretingresultsfromthesedatabases.
Firstly,thesamplingunitsaredifferent.TheCPRDcontainsdatafrompatients inpractices
which agree to participate in. In the February 2014 version of the CPRD, there are 680
participatingpractices.Table2 ?4showsthenumbersofparticipatingpracticesin13areasin
theUK.Itisobviousthatthedistributionofpracticesisnotevenacrossthecountry.In2012,
registered patients residing in England, Scotland,Wales andNorthern Ireland comprised
78.71%, 9.59%, 8.81% and 2.89% respectively.As shown in Table 2 ?5, England is slightly
underrepresentedandWales isoverrepresentedcomparingwithmid ?yearcensus in2012
accordingtoOfficeofNationalStatistics. Inaddition,practicescan joinor leavetheCPRD,
thereforethenumberofpracticesinCPRDisnotstableovertime.Briefly,thedatainCPRD
































Number (%) of patients in 
CPRD in 2012 
Number (%) of mid-year 
population in 2012 
England 5165256 (78.71) 53107200 (83.97) 
Scotland 629110 (9.59) 5299900 (8.34) 
Wales 578232 (8.81) 3063800 (4.83) 
Northern Ireland 189809 (2.89) 1814300 (2.86) 




clinically oriented and contains laboratory and examination results data.No data on fee
incurringduringaconsultation isavailable.Thedata intheNHIRDaremoreadministrative
oriented. The information on various kinds of incurred fees generated bymedical staff







Thirdly, the scopeof thesedatabases isdifferent.TheCPRD isessentially aprimary care
databasewithexternallinkages.Thecoverageofthemaindatabaseandlinkagesdiffer,with
the linkages beingmore limited in coverage. For example,ONSmortality data,HES and
socioeconomic data are limited to English practices consenting to linkages. The NHIRD
containsdatafromtheentirehealthservice inTaiwan.This isbecausetheNationalHealth
Insuranceisasinglepayersystemwithamandatoryenrolment.Privatehealthservicesare










gout identification (see table 2 ?3). The case definition has been validated in a previous
study.(MeierandJick,1997)Meieretalreviewedmedicalrecordsandlaboratoryresultsof

























1443 H/O:gout + 
6691 Initialgoutassessment + 
6692 Follow ?upgoutassessment + 
6693 Jointsgoutaffected + +
6695 Dategouttreatmentstarted + 
6696 Dateoflastgoutattack + 
6697 Goutassociatedproblems + 
6698 Goutdrugsideeffects + 
6699 Gouttreatmentchanged + 
669..00 Goutmonitoring + 
669A.00 Dategouttreatmentstopped + 
669Z.00 GoutmonitoringNOS + 
C34..00 Gout + +
C340.00 Goutyarthropathy + +
C341.00 Goutynephropathy + +
C341z00 GoutynephropathyNOS + +
C342.00 Idiopathicgout + +
C345.00 Goutduetoimpairmentofrenalfunction + +
C34y.00 Otherspecifiedgoutymanifestation + +
C34y000 Goutytophiofear + +
C34y100 Goutytophiofheart + +
C34y200 Goutytophiofothersites + +
C34y300 Goutyiritis + +
C34y400 Goutyneuritis + +
C34y500 Goutytophiofhand + +
C34yz00 OtherspecifiedgoutymanifestationNOS + +
80
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C34z.00 GoutNOS + +
G557300 Goutytophiofheart + +
N023.00 Goutyarthritis + +
N023100 Goutyarthritisoftheshoulderregion + +
N023200 Goutyarthritisoftheupperarm + +
N023300 Goutyarthritisoftheforearm + +
N023400 Goutyarthritisofthehand + +
N023600 Goutyarthritisofthelowerleg + +
N023700 Goutyarthritisoftheankleandfoot + +
N023800 Goutyarthritisoftoe + +
N023x00 Goutyarthritisofmultiplesites + +
N023y00 Goutyarthritisofotherspecifiedsite + +




For theNHIRD, thecompleteoutpatient recordsdatabasewas screened forpatientswho
required2ormoretreatmentsforDM(ICD ?9code:250),hypertension(ICD ?code:401 ?405),
coronaryheartdisease(CHD; ICD ?9code:411 ?414),orstroke (ICD ?9code:430 ?438).Since
end ?stage renaldisease (ESRD) requiring renal replacement therapynecessitates that the
































































































































Themost importantmedications used by gout patients areULT (allopurinol, febuxostat,
benzbromarone, sulphinpyrazone, and probenecid) and colchicine. The specific codes of
thesedrugsarelistedintheappendix.
 Identificationofkinshipsandascertainmentoffamily
Thedefinitionofa family in this studywasa clusterof individualswhowere first ?degree
relatives (father,mother, son, daughter, brother, and sister) or who have at least one





It is importanttonotethattherelationshipbetweenthe insuredandthedependentsmay
changeovertime.Forinstance,childrenmayregisterindependentlyaftertheyhavejobsand
theymayalsoserveas the insuredonce theyaremarriedandhavechildren.The registry
updatesannually.Tomaximisethepossibilityofrelationshipidentification,alltherelationship
recordedintheNHIRDbetween1996and2010wereutilised.Duringtheperiod,therewere




The first step in the identificationofkinship is toascertainparent ?offspring relationships.
Directparenthoodwas recorded in the registry. Indirect identificationofparent ?offspring
relationshipisalsopossible.Aparent ?offspringrelationshipexistsbetweengrand ?parentsand




spouse andoffspring shouldbe in the sameperiod inorder toestablishparent ?offspring
relationship.Grand ?parentsof an individualwere identified asparentsof the individual's
parents. Grand ?children of an individual were identified as children of the individual's
children.After considerationof all the aforementioned scenarios, therewere 18,695,180
pairsofparent ?offspringrelationships.
Thenextstepistoascertainsiblingsofanindividual.Theidentificationofsiblingswasbased
on sharing one ormore common parents. In this study half ?siblingswere not examined
although identificationofhalf ?siblings ispossible.Only spouses from firstmarriageswere
































































































Gout is the most common inflammatory arthritis with a diverse spectrum of clinical
manifestations. In addition to recurrent acute arthritis, subcutaneous tophi and chronic
painfularthritis,(Zhangetal.,2006b)italsohasanimpactonmorbidity(Abbottetal.,1988,
Krishnanetal.,2006,SheaneandCunnane,2007)andprematuremortality.(ChoiandCurhan,
2007, Krishnan et al., 2008, Kuo et al., 2010a) Gout results from the deposition of



















Currently,UKdata from thecurrentmillenniumexploringgout incidenceandprevalence,
assessedatmultipletimepointsinthesamepopulation,aresparse.Therefore,thisstudywas











1997 and 31th December 2012. The denominator for prevalence estimation (eligible














the year. To be eligible as an incident case, participants had to have at least one ?year





































(thosewithaPDCof20% to79%)andadherent (thosewithaPDCofat least80%).The
management of incident gout patientswas assessed by the percentage of incident gout
patientstreatedwithULTat6monthsandoneyearafterdiagnosis.
 Trendsofprevalence,incidenceandmanagementofgout
Todetermine the trendsofprevalence, incidenceandmanagementofgout the following
were calculated: the age ?, sex ?and length of data contribution ?standardised prevalence,
incidenceof gout andpatternofULT in each calendar year from 1997 to 2012with the

















































Of4,634,974eligible individuals in2012,115,608prevalentcasesofgoutwere identified,




























































 N Crude Standardised  Person-
years
Crude Standardised
























































































































































































Figure3 ?6Managementof gout (a) standardisedpercentageofprevalentpatients
undermedicalattention(blue line),andtreatedbyurate ?loweringagents(red line)






AmongULT ?treatedpatients in2012 (n=49395),39.66% (95%CI,39.11%വ40.22%)were
adherenttotreatment.Partiallyadherentandnon ?adherentpatientscomprised42.84%(95%
CI, 42.27%വ43.42%) and 17.50 (95% CI, 17.13%വ17.87%), respectively. In contrast to the
percentageofpatientsreceivingULT,patientadherencetoULTimprovedinthepast16years
















on primary definition, alternative definition one and alternative definition 2were 2.49%
(2.48%വ2.51%), 2.27% (2.26%വ2.29%) and 1.39% (1.38%വ1.40%), respectively (table 4 ?2).
Prevalencebasedonalternativedefinitiononeandtwowereapproximately91%and56%
thatofestimatebasedonprimarycasedefinition,respectively.Thispatternisconsistentin
estimatesacrossperiod1997 ?2012.Male to female ratiowas slightlyhigher inestimates
basedonalternativedefinitions;4.4fordefinition1and3.9fordefinition2.Figure4 ?8shows
age ?specificprevalenceofgoutin2012basedondifferentcasedefinitions.Itisapparentthat
the trends are similar.Estimatesbasedonprimary casedefinition showsnearly identical
pattern with alternative case definition one, while estimates based on alternative case
definitiontwoshowsaproportionallylowerestimatesacrossages.
In2012, the incidenceofgoutbasedonprimarydefinition,alternativedefinitiononeand
alternativedefinition 2were 1.77 (1.73വ1.81), 1.70 (1.66വ1.74) and 0.85 (0.83വ0.88) per
1,000person ?years,respectively.Incidencebasedonalternativedefinitiononeandtwowere
approximately97%and54%thatofestimatebasedonprimarycasedefinition,respectively.






















 Prevalence (%) Incidence
(per 1000 person-years)












1997  2209057 1.42 (1.40௅1.43) 1.22 (1.20௅1.23) 0.78 (0.77௅0.80) 2069698 1.35 (1.30௅1.40) 1.31 (1.26௅1.36) 0.70 (0.66௅0.73) 
1998  2592984 1.46 (1.45௅1.48) 1.20 (1.18௅1.21) 0.77 (0.75 ௅0.78) 2430671 1.29 (1.25௅1.34) 1.25 (1.21௅1.30) 0.69 (0.66௅0.73) 
1999  3138413 1.47 (1.45௅1.48) 1.19 (1.18௅1.20) 0.77 (0.76௅0.78) 2937813 1.39 (1.35௅1.43) 1.34 (1.30௅1.39) 0.76 (0.73௅0.79) 
2000  3554201 1.48 (1.47௅1.49) 1.30 (1.29௅1.31) 0.84 (0.83௅0.85) 3318520 1.42 (1.38௅1.46) 1.38 (1.34௅1.42) 0.79 (0.76௅0.82) 
2001  3929216 1.53 (1.52௅1.55) 1.33 (1.32௅1.34) 0.86 (0.85௅0.87) 3668822 1.54 (1.50௅1.58) 1.50 (1.46௅1.54) 0.85 (0.82௅0.88) 
2002  4209993 1.59 (1.58௅1.61) 1.42 (1.41௅1.43) 0.92 (0.91௅0.93) 3912097 1.58 (1.54௅1.62) 1.55(1.51௅1.58) 0.88 (0.85௅0.91) 
2003  4375751 1.67 (1.66௅1.69) 1.50 (1.49௅1.51) 0.97 (0.96௅0.98) 4060357 1.65 (1.61௅1.69) 1.61 (1.57௅1.65) 0.90 (0.87௅0.93) 
2004  4516966 1.76 (1.74௅1.77) 1.60 (1.59௅1.62) 1.04 (1.03௅1.05) 4202025 1.67 (1.63௅1.71) 1.63 (1.59௅1.66) 0.93 (0.90௅0.96) 
2005  4605171 1.86 (1.85௅1.87) 1.71 (1.70௅1.73) 1.10 (1.09௅1.11) 4299261 1.74 (1.70௅1.78) 1.70 (1.66௅1.74) 0.96 (0.93௅0.99) 
2006  4684243 1.96 (1.95௅1.98) 1.79(1.77௅1.80) 1.14 (1.13௅1.15) 4334086 1.70 (1.67௅1.74) 1.66 (1.62௅1.70) 0.92 (0.90௅0.95) 
2007  4736672 2.03 (2.02௅2.05) 1.87 (1.86௅1.88) 1.19 (1.18௅1.20) 4374944 1.67 (1.63௅1.71) 1.62 (1.58௅1.66) 0.91 (0.88௅0.94) 
116

2008  4729771 2.16 (2.14௅2.17) 1.97 (1.96௅1.98) 1.25 (1.24௅1.27) 4384072 1.75 (1.71௅1.79) 1.70 (1.67௅1.74) 0.95 (0.92௅0.98) 
2009  4727886 2.25 (2.24௅2.26) 2.06 (2.04௅2.07) 1.30 (1.29௅1.31) 4384787 1.73 (1.69௅1.77) 1.67 (1.64௅1.71) 0.90 (0.87௅0.93) 
2010  4741179 2.31 (2.30௅2.33) 2.10 (2.09௅2.11) 1.31 (1.30௅1.32) 4351414 1.68 (1.65௅1.72) 1.63 (1.59௅1.67) 0.83 (0.80௅0.86) 
2011  4624055 2.40 (2.39௅2.42) 2.19 (2.18௅2.20) 1.35 (1.34௅1.36) 4235444 1.75 (1.71௅1.79) 1.69 (1.65௅1.73) 0.85 (0.82௅0.88) 


































































































































































Early studies showed an increase in gout prevalence in the UK up until 1999, when a
nationwide study by Mikuls et al. using the GPRD reported an overall prevalence of
1.39%.(Mikulsetal.,2005b)UsingtheIMDanalyserintheperiod2000വ2005,Annemanset
al. reported an identical prevalence of 1.4% suggesting that gout prevalencemay have
reachedaplateau.(Annemansetal.,2008)Incontrast,theprevalenceestimateswereslightly
higherduringtheperiod1999വ2005andcontinuedtoincreasethroughoutthestudyperiod.
It ispossiblethatthisdisparityprimarilyresults fromdifferentdegreesof identificationof
clinicallysilentpatients,whoseidentificationdependsonaperiodofdatacontributionthatis






10years in7%of614patients.(YuandGutman,1961)Therefore, rather than requiringa
minimallengthofdatacontribution,directstandardisationconsideringage,sexandlengthof
data contributionwasutilised to circumvent the incomplete identificationof inter ?critical
gout patients. Studies that have not examined prior data contribution will have











person ?years in the adult population in the period 2000വ2007.(Elliot et al., 2009) The
estimatesof incidence in thepresent study ingeneral fallwithin theseprevious reported




























thedisease remainspoor. Throughout1997വ2012only aroundone thirdofpeoplewith
prevalent gout were prescribed ULT. The management for incident gout patients also
remainedunchangedwithonlyaquartertoathirdofpatientsbeingtreatedwithULTwithin
oneyearofdiagnosis.ThisshowsnosignificantchangeinoverallusageofULTfromMikuls
estimates of 25.3% ?29.5% from 1990 to 1999(Mikuls et al., 2005b). Apart from under ?
prescribingofULT,MikulsetalidentifiedinappropriateprescribingofULTinonequarterto
onehalfofthosepeopleinwhomqualityindicatorscouldbeassessed(Mikulsetal.,2005a)
and a more recent study also demonstrated suboptimal care in many aspects of gout























2012.Althoughprevious studies largelyblamepatients forpoor adherence,(Reach,2011,










Thereare several limitations to the study.Firstly, this studybased the casedefinitionon
diagnosis by the general practitioners, rather than according to American College of
Rheumatology(Wallaceetal.,1977)orRome(KellgrenJH,1963)classificationcriteriaortothe
'gold standard' of urate crystal identification and thismay lead tomisclassification bias.
However,thevalidityofgoutdiagnosisintheCPRDhasbeeninvestigatedandfoundtobe




definitionwere lower than estimates based on physician diagnosis alone. However, the













are the highest reported within Europe. However, despite being the commonest
inflammatoryarthritisthesuboptimalmanagementofgoutcontinuesunchanged,withonly
aminorityofpatientsreceivingULTandnewpatientsnotbeingtreatedinatimelyfashion.
Althoughsomewhat improvedpatientadherencetoULTremainspoor.  It isapparentthat














Health InsuranceResearchDatabase (NHIRD).(Kuo et al., 2013b) In particular, Taiwanese
aborigineshaveaveryhighprevalenceofgout(Changetal.,1997,ChouandLai,1998),which
issharedwiththeirgeneticallyrelatedPolynesiancousins,theMaoriandindigenousOceanic ?
Pacific Islanders.(Klempetal.,1997) Incidenceofgouthasnotbeenestimated inTaiwan
previously and the current standard of care in Taiwan as reflected by the use of urate ?
loweringtherapyhasnotbeenexamined.
Thereforethisstudywasundertakentoexaminetheprevalenceandincidenceofgoutand
the patterns of gout management between 2005 and 2010 using the National Health

































risk cohorts were constructed for each calendar year which comprised all individuals
registeredduringthegivencalendaryearwhohadnohistoryofgoutdiagnosisbefore1stJan
of the year. Incidencewas calculated using the number of incident gout cases during a
calendaryearasthenumeratorandthetotalperson ?yearsat ?riskpopulationaccumulated
duringthatyearasthedenominator.























cases. The Joinpoint Regression Program (version 4.0.4)was used to estimate trends in























































































































































but standardised prevalence fluctuated throughout the study period. The standardised









incidence decreased significantly during the study period (figure 5 ?2b). On average, the
annualpercentagechangeofgoutincidencewas ?7.9(95%CI, ?10.7to ?5.0)andtherewas
onejoinpoint(2007).Theannualpercentagechangeofincidencewas ?13.4(95%CI, ?16.1to







Table 4 ?1 Crude and standardised prevalence and incidence of gout from 2005 to
2010
Year  Prevalence (%) Incidence (per 1000 person-years) N Crude Standardised Person-years Crude Standardised
Overall
2005  23,000,521 5.91 (5.90௅5.92) 6.44 (6.43௅6.45) 20,675,205 3.89 (3.86௅3.92) 4.09 (4.06௅4.11)
2006  23,127,946 6.14 (6.13௅6.15) 6.58 (6.57௅6.59) 20,502,927 3.29 (3.27௅3.32) 3.43 (3.41௅3.46)
2007  23,221,905 6.22 (6.21௅6.23) 6.55 (6.54௅6.56) 20,569,401 2.97 (2.95௅2.99) 3.06 (3.04௅3.09)
2008  23,315,001  6.27 (6.26௅6.28) 6.49 (6.48௅6.50) 20,616,155 2.95 (2.93௅2.98) 3.01 (2.99௅3.04)
2009  23,344,259 6.30 (6.29௅6.31) 6.41 (6.40௅6.42) 20,633,487 2.83 (2.80௅2.85) 2.86 (2.85 ௅2.88)
2010  23,371,362 6.24 (6.23௅6.25) 6.24 (6.23௅6.25) 20,633,895 2.73 (2.71௅2.75) 2.73 (2.71௅2.75)
Men     
2005  11,550,180 8.35 (8.33௅8.36) 9.01 (8.99௅9.02) 10,021,292 5.67 (5.62௅5.71) 5.94 (5.89௅5.98)
2006  11,579,907 8.74 (8.72௅8.76) 9.28 (9.27௅9.30) 9,974,293 4.78 (4.73௅4.82) 4.93 (4.89௅4.98)
2007  11,598,597 8.98 (8.96௅8.99) 9.40 (9.38௅9.41) 9,952,078 4.37 (4.33௅4.42) 4.48 (4.44௅4.53)
2008  11,615,445 9.16 (9.14௅9.18) 9.45 (9.43௅9.47) 9,926,917 4.34 (4.30௅4.38) 4.41 (4.37௅4.45)
2009  11,597,439 9.32 (9.30௅9.34) 9.47 (9.45௅9.48) 9,889,211 4.18 (4.14௅4.22) 4.21 (4.17௅4.25)
2010  11,583,208 9.34 (9.32௅9.36) 9.34 (9.32௅9.36) 9,845,586 4.06 (4.02௅4.10) 4.06 (4.02௅4.10)
Women    
2005  11,450,341 3.46 (3.45௅3.47) 3.92 (3.91௅3.93) 10,468,285 2.22 (2.19௅2.25) 2.46 (2.43௅2.49)
2006  11,548,039 3.54 (3.53௅3.55) 3.92 (3.91௅3.93) 10,528,634 1.89 (1.86௅1.91) 2.06 (2.03௅2.09)
2007  11,623,308 3.48 (3.47௅3.49) 3.76 (3.75௅3.77) 10,617,323 1.65 (1.63௅1.68) 1.76 (1.74௅1.79)
2008  11,699,556 3.40 (3.39௅3.41) 3.59 (3.57௅3.60) 10,689,238 1.67 (1.64௅1.69) 1.74 (1.72௅1.77)
2009  11,746,820 3.31 (3.30௅3.32) 3.41 (3.40௅3.42) 10,744,276 1.58 (1.56௅1.61) 1.62 (1.59௅1.64)











































































































































for gout or been treatedwithULT (n = 515,004; 35.31% [95% CI, 35.23%വ35.39%]).
However,onlyone in fiveprevalentgoutpatients in2010were treatedwithULT (n=
334,518;22.93%[95%CI,22.87%വ23.00%]).AmongULT ?treatedpatients60.08%(95%CI,
59.91%വ60.25%) received uricosuric agents alone, 28.54% (95% CI, 28.39%വ28.69%)
received a xanthineoxidase inhibitor, and 11.38% (95%CI, 11.27%വ11.49%) received
both.Asshown inFigure5 ?4a,theproportionofprevalentpatientswhoconsultedfor






Figure 4 ?4 Treatment of gout in Taiwan in 2010. Proportion of prevalent gout
patientshavingconsulted forgoutorreceivingurate loweringtreatment (black








































Figure5 ?6 showsa comparisonofgout incidencebetweengenders. It isobvious that
prevalenceofgoutisconsistenthigherinTaiwanthanintheUKinbothmenandwomen
acrossallagebands.Asimilartrendwasfoundintheincidenceofgout,onlyinpeople









ULTwasmore limited in theUK,where only allopurinol is routinely available forGP




inhibitor, febuxostat,which has been approved in both countries. The utilisation of
febuxostatisnotdiscussedherebecauseitisapprovedin2011,whichyearisbeyondthe
studyperiod.Ingeneral,bothcountriessufferlowULTprescriptionrateandthepattern
did not change in recent years. In addition, this proportion remains stable in both
countriesduringtheperiod2005 ?2010.Ahigherproportionofprevalentpatientswere
































































































































prevalence and incidence of gout was observed. In a population of 23million people,
approximatelyone in16 residentsofTaiwan isaffectedbygout.Despitea trend toward
decreasingincidence,theprevalenceofgoutwasfairlystableovertheperiodbetween2005
and 2010. Despite the small size of Taiwan (only 36,193 km2) both the prevalence and
incidence of gout showedmarked geographical variation. This regional variation in gout
generallycoincideswiththedistributionofaboriginalpeopleinTaiwanwhoprimarilyreside













the latersurveyconducted in2005 ?2008foundaprevalenceofgoutof8.21% inmenand
2.33%inwomen.(Chuangetal.,2011)However,theseestimateswerebasedonself ?reported











gout patients diagnosed by this means in 2000 also reported gout in the follow ?up
questionnaire in2003andonly65% in the2003and2007questionnaires.AnotherDutch
studyfoundthatonly64%ofgoutpatientsself ?reportedgoutafterjust6monthsoffollow ?
up (Picavet andHazes, 2003). Furthermore an earlier study found that only 44% of self ?
reported gout cases had this confirmed bymedical chart review and physician interview






previous study and 10 years in the current study) and therefore different degrees of
identificationofclinicallysilentpatients.Itisdifficulttodeterminetowhatextentashorter






















1.77 per 1000 person ?years.(Kuo et al., 2014) However, all these estimates relate to










National Studies of Morbidity in General Practice and the Framingham study, each
undertakeninthe1980s,foundthatgoutincidencepeakedaroundthe50sageband.(Abbott
etal.,1988,StewartandSilman,1990)Morerecently,MikulsetalusingtheGeneralPractice










and 84 years. This appears unique compared with previous studies on age ?specific
incidence,(Abbottetal.,1988,StewartandSilman,1990,Mikulsetal.,2005b)whichreporta
linear increase inthe incidenceofgoutwithageuptothepeakandthena levellingoffor





reflectthecompositionofTaiwaneseresidents   ?amixtureofHanChineseand indigenous
people,whoareknowntobeverypronetogout(Changetal.,1997,Koetal.,2002)andwho
are genetically related to gout ?stricken Polynesians and Oceanic Pacific
Islanders.(Friedlaenderetal.,2008)Thispopulationstratificationwasalsodemonstratedby
the regional variation in gout prevalence and incidence since the areas with highest




















knowledge and interest in gout among primary care physicians,which in turn reflects a
numberofvariedbarrierstooptimalcareofgoutpatients.(Dohertyetal.,2012,Spenceret








Thereare several limitations to this study.Firstly, this studybased thecasedefinitionon

























Current guidelines and recommendations endorsed by the European League against
Rheumatism(EULAR),(Zhangetal.,2006a)AmericanCollegeofRheumatology(ACR)(Khanna
et al., 2012a) and British Society of Rheumatology (BSR)(Jordan et al., 2007) concur in
recommendingdietcontroland life stylechanges forallgoutpatients.ULTwithxanthine
oxidaseinhibitorsoruricosuricagentsaregenerallyrecommendedbytheseguidelinesonly
forpatientswithmoreseveredisease(suchasthepresenceoftophiorradiographicchanges)
orwith other concomitant conditions (such as the presence of urolithiasis, poor kidney
functionanduseofdiuretics)thatmeritearlierULT.Thereisagreementthatmanagement
































more consultations for gout with prescription of non ?steroid anti ?inflammatory drugs
(NSAID),colchicineorcorticosteroidat leastthreemonthsapartafterthefirstdiagnosisof


























(642 intheentiredatabase)practices included intheCPRD.Theproportionofprescription
varianceexplained(R ?squared)bypatient ?levelfactors(ageatdiagnosis,gender,ethnicity,
quintiles of 2004 Index ofMultiple deprivation [IMD], year of gout diagnosis, Charlson
comorbidityindex[validatedversionfortheusewithReadcodeddata(Khanetal.,2010b)]




factors thataffect theprescriptionofULT,Coxproportionalhazardmodelswereused to
estimatehazardratios(HRs)with95%confidenceintervals(CIs)usingyearssincethedateof
firstgoutdiagnosisas the time toeventoutcome.Similaritiesofpatientswithinpractices
were considered by using a marginal model with robust sandwich estimate.(Lin, 1994)
Covariateswere theaforementionedpatient ?andpractice ?level factors.Ageand fulfilling
specific indicationsforULTweretime ?dependentcovariates,whichweremodelledusinga
























Ageatdiagnosis(years) 62.5 ±15.2 60.1 ±14.9 69.2±14.2
Agedistribution(n,%) 
<35years 1,855 (3.56) 1,585 (4.14) 270(1.94)
35വ49years 9,482 (18.18) 8,404 (21.96) 1,078(7.76)
50 ?64years 15,906 (30.49) 12,629 (33.00) 3,277(23.59)
ш65years 24,921 (47.77) 15,654 (40.90) 9,267(66.71)
Yearsoffollow ?up(median,interquartilerange) 6(4വ9) 6(4വ9) 5(3വ8)
Ethnicity(n,%) 
Caucasians 25,629 (49.13) 17,909 (46.79) 7,720(55.57)
Black 406 (0.78) 300 (0.78) 106(0.76)
Asian 190 (0.36) 135 (0.35) 55(0.40)
Other 5,925 (11.36) 4,314 (11.27) 1,611(11.60)
Unknown 20,014 (38.37) 15,614 (40.80) 4,400(31.67)
Socioeconomic 
Quintile1(leastdeprived) 10,390 (19.92) 7,885 (20.60) 2,505(18.03)
Quintile2 9,357 (17.94) 6,960 (18.19) 2,397(17.25)
Quintile3 8,109 (15.55) 5,939 (15.52) 2,170(15.62)
Quintile4 6,647 (12.74) 4,673 (12.21) 1,974(14.21)
Quintile5(mostdeprived) 4,427 (8.49) 3,100 (8.10) 1,327(9.55)
Unknown 13,234 (25.37) 9,702 (25.38) 3,519(25.33)
Charlsoncomorbidityindex(n,%) 
0 29,120 (55.82) 22,890 (59.81) 6,230(44.85)
1വ2 1,676 (3.21) 1,008 (2.63) 668(4.81)
3വ4 16,573 (31.77) 11,327 (29.60) 5,246(37.76)
5വ6 3,806 (7.30) 2,426 (6.34) 1,380(9.93)
ш6 989 (1.90) 621 (1.62) 368(2.65)
Yearofdiagnosis 
1997വ1998 4,006 (7.68) 2,951 (7.71) 1,055(7.59)
1999വ2000 5,717 (10.96) 4,199 (10.97) 1,518(10.93)
2001വ2002 7,443 (14.27) 5,478 (14.31) 1,965(14.14)
2003വ2004 8,382 (16.07) 6,119 (15.99) 2,263(16.29)
2005വ2006 8,941 (17.14) 6,520 (17.04) 2,421(17.43)
2007വ2008 8,890 (17.04) 6,522 (17.04) 2,368(17.05)






attacks were 29.16% in the first year and 46.46% in the second year from diagnosis.






Table 5 ?2 Cumulative probability of ULT prescription or fulfilling specific
indicationsforULTbygender

































                
Further
attacks
0 29.16 46.46 57.05 70.02 83.74 0 28.00 45.74 56.87 70.52 84.63 0 32.34 48.45 57.52 68
Tophi 0.46 0.51 0.57 0.63 0.74 1.09 0.27 0.31 0.35 3.39 0.48 0.75 0.98 1.09 1.17 1.28 1
Urolithiasis 1.72 1.80 1.91 1.99 2.15 2.64 1.93 2.02 2.14 2.23 2.41 2.93 1.15 1.20 1.28 1.32 1
CKD 22.98 25.85 29.09 31.98 37.53 47.11 17.30 19.68 22.36 24.79 29.75 39.15 38.62 42.84 47.66 51.81 58

 PercentagesofpatientsfulfillingULTatdiagnosisandtheendofthestudy
Asshown inTable6 ?2,approximately two ?thirdsofwomen (67.10%)andone ?thirdof
men(36.19%)withgoutfulfilledindicationsforULTatthetimeoffirstdiagnosis.Themost
common indications forULTat firstdiagnosiswereuseofdiuretics (36.83%)andCKD
(23.12%), whereas the presence of tophi (0.47%) and urolithiasis (1.73%) were
uncommonatfirstpresentation.Thevastmajorityofpatients(87.49%)wereeligiblefor
ULTat theendof follow ?up (medianof5yearsduration)andwomenbecameeligible





















ULTeligiblepatients(n,%) 23,172 (44.42) 13,851(36.19) 9,321 (67.10)
Eligibleduetotophi(n,%) 246 (0.47) 106(0.28) 140 (1.01)
Eligibleduetourolithiasis(n,%) 902 (1.73) 742(1.94) 160 (1.15)
Eligibleduetochronickidneydisease(n,%) 12,062 (23.12) 6,663(17.41) 5,399 (38.86)
Eligibleduetodiureticuse(n,%) 19,212 (36.83) 11,119(29.05) 8,093 (58.26)
Eligibilityandtreatmentattheendofstudy
ULTeligiblepatients(n,%) 45,637 (87.49) 32,775(85.64) 12,862 (92.59)
Eligibleduetofurtherattacks(n,%) 36,593 (70.15) 27,158(70.96) 9,435 (67.92)
Eligibleduetotophi(n,%) 444 (0.85) 223(0.58) 221 (1.59)
Eligibleduetourolithiasis(n,%) 1,204 (2.31) 991(2.59) 213 (1.53)
Eligibleduetochronickidneydisease(n,%) 21,111 (40.47) 12,540(32.77) 8,571 (61.70)
Eligibleduetodiureticuse(n,%) 25,617 (49.11) 15,872(41.47) 9,745 (70.15)






indicationwas5.00 (95%CI,4.70 to5.30)monthsand thecumulativeprobabilitiesof
fulfillingULTindicationswere44.26%,61.02%,72.11%,78.87%,86.81%and94.27%at0,
1,2,3,5,and10years fromdiagnosis,respectively.Womenweremore likelyto fulfil













different age groups. Despite younger patients tending to have lower likelihood of








































Although existing guidelines provide specific indications for ULT in patients with gout,
currentlythere isnoexplicitevidence ?basedadviceconcerningwhen inthecourseofgout
patientsshouldbeconsidered forULT,particularlyaround the timeofdiagnosis. Current
trends increasingly favourearly treatmentwithULT topreventpeopledeveloping further
crystaldepositionandlong ?termcomplications,suchassubcutaneoustophiandjointdamage
ratherthanwaituntilthesehaveoccurred.(Dohertyetal.,2012)Sincefrequentattacks,CKD,
urolithiasis, diuretic use and tophi(McGill and Dieppe, 1991) are specific indications for
ULT,(Zhangetal.,2006a,Jordanetal.,2007,Khannaetal.,2012a,Siveraetal.,2014) it is
conceivablethatthemajorityofgoutpatientsshouldbetreatedearly.Balancedagainstearly
rather than late ULT are the concerns over rare but serious side effects from










et al., 2006a) British Society for Rheumatology and British Health Professionals in
Rheumatology(Jordanet al.,2007) andAmericanCollegeofRheumatology(Khannaet al.,
2012a)generallyadvisedietaryandlifestylemodificationastheinitialsteptomanagegout.
ULT is indicated for patients showing evidence of uncontrolled arthritis, joint damage,
excessiveurate load (suchas tophiorurolithiasis)orhavingconditions thatmaypromote
long ?standinghyperuricaemia(renaldiseaseoruseofdiuretics).However,goutpatients in





Even if patients are not eligible at diagnosis, they often fulfil theULT indications due to






















foran acuteattack.Therefore theestimatesofcumulativeprobabilityof furtherattacks
were lower in thisstudy thanaprevious largeseries,which found62%ofuntreatedgout
patientshadattackwithinoneyear.(YuandGutman,1961)Furthermoretheprevalenceof






In conclusion, themajority of gout patients are eligible forULT ator shortly after initial














andHarvald, 1955, Smyth et al., 1948a, Smyth et al., 1948b,Grahame and Scott, 1970,
Copeman,1964,Cobb,1971,Reginatoetal.,2012)however,theexistenceofmanyknown
risk factors,suchasmalegender, increasingage,(Arromdeeetal.,2002,MikulsandSaag,





High heritability of hyperuricaemia, (Wilk et al., 2000) themain driver of urate crystal
depositionandthedevelopmentofgout,hasledtoeffortstoidentifysusceptibilitygenes.A
large familial segregation study has demonstrated significant heritability for
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hyperuricaemia(Wilk et al., 2000) and specific genetic associations, particularly genes








failed to identify susceptibility genes to gout beyond genes controlling serum urate
concentration,thusquestioningtheroleofgeneticfactorsingout.(Kottgenetal.,2013)
Therefore for this thesis the first nationwide population ?based studywas undertaken to
estimatethedegreeoffamilialaggregationofgoutandtheextenttowhichheritabilityanda
common familial environment might each account for familial aggregation. This was
undertaken in Taiwan because firstly, Taiwan has the one of the highest reported gout
prevalenceworldwide(Lin et al., 2000) and secondly, there is an established nationwide











personal identifierassigned toeachTaiwanese resident,whichallowsaccurate linkageof
records from the registration files and from the original claims data. Before release for
research,personalidentifiersarede ?identifiedtoensureconfidentiality.
Theregistryofbeneficiaries,oneoftheregistrationfiles,containsdetailsofdemographics,
residence, kinship relationships, occupation categories, insurance status and insurance
amountofallbeneficiariesofNHI.Claimsdataonalloutpatientvisits, inpatientcareand
pharmacydispensingwererecorded inspecificdatasetswith informationsuchasdatesof










The primary case definition of gout was having a physician recorded diagnosis of gout
(InternationalClassificationofDiseases,NinthRevision[ICD ?9]code:274.x)togetherwithat
least one prescription containing gout ?specific medications (colchicine, benzbromarone,
allopurinol,probenecid, sulfinpyrazone)ateitheranoutpatientoremergencyvisitduring
20002004.Analternativedefinition,usedforsensitivityanalysis,washavingtwooutpatient




fee and his/her dependents, allowing parent ?offspring relationships and spouses to be





same date of birth (±1 day). Second ?degree relatives were ascertained based on the
aforementioned relationships.These linksallowed the identificationof4,191,274 families
spanning25generations.
 Demographicsandsocioeconomicinformation
Socioeconomic factorswere also examined, including residence,occupations and income
levels, to reflect population stratification with the aboriginals (with significantly higher
prevalenceofgout(LiuCY,2006))andHanpeopleinTaiwan.
Theresidenceforeach individualwasassignedasoneof369townsordistricts inTaiwan,




categories: (1) civil servants, teachers,military personnel and veterans; (2) non ?manual
workers and professionals; (3) manual workers; (4) other and (5) the
unemployed/dependents. Income levelswere approximated based on the payroll ?related
amount,whichwasdeterminedbythepayrolloftheemployeesandcivilservantsandthe



























and second ?degree relatives, age and sex were taken into account and age ?and sex ?


















where ߪH?ൌ ݐ݋ݐ݈ܽ݌݄݁݊݋ݐݕ݌݅ܿݒܽݎ݅ܽ݊ܿ݁ ; ߪH?ൌ ܽ݀݀݅ݐ݅ݒ݁݃݁݊݁ݐ݅ܿݒܽݎ݅ܽ݊ܿ݁ ; ߪH?ൌܿ݋݉݉݋݊݁݊ݒ݅ݎ݋݊݉݁݊ݐ݈ܽݒܽݎ݅ܽ݊ܿ݁;andߪH?ൌnon ?sharedenvironmentalvariance.
Theheritabilitywasdefinedastheproportionofphenotypicvariancethatisattributableto
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 Goutprevalence in individualswithaffected familymembers versus the general
population
The study identified 802,765men and 242,294womenwith gout in 2004 giving a crude
prevalenceofgoutof4.62%(95%CI,4.61%4.63%)(Table3 ?1).Menhadasignificantlyhigher
prevalence(7.07%,95%CI,7.05%7.08)thanwomen(2.15%,95%CI,2.14%2.16%).There
were 1,663,904 individuals with at least one affected first ?degree relative and 604,468
individualswithatleastoneaffectedsecond ?degreerelative.Thestandardisedprevalenceof
gout in individualswith affected first ?and second ?degree relativeswere13.37% (95%CI,
13.35%13.39%)and10.05%(95%CI,10.03%10.06%) inmenand4.16%(95%CI,4.15%
4.18%)and3.01%(95%CI,3.00%3.02%)inwomenrespectively.Figure3 ?1aand3 ?1bshow
















Age(years)(mean±standarddeviation) 29.8±18.4 34.9±20.8  30.0±19.8 35.2±20.5
Gout(%) 10.79 7.07 3.13 2.15
Placeofresidence(%)  
Urban 60.16 57.53 61.39 59.40
Suburban 30.86 32.15 29.39 30.39
Rural 5.75 7.49 5.75 7.40
Aboriginal 3.23 2.83 3.47 2.81
Incomelevels(%)  
Quartile1 24.27 27.68 24.49 27.77
Quartile2 25.37 27.52 26.44 30.18
Quartile3 22.20 19.60 18.79 16.84
Quartile4 28.16 25.20 30.28 25.21
Occupation(%)  
Dependentsoftheinsuredindividuals 41.07 34.49 49.97 42.39
Civilservants,teachers,militarypersonnelandveterans 5.25 4.39 4.09 3.04
Non ?manualworkersandprofessionals 30.53 29.33 27.17 25.81
Manualworkers 14.50 20.28 12.52 21.57



































Affected first- and second-
degree relatives
Men at risk Women at risk












































































































































































































































Affectedrelativesofgout   
Norelativeaffected 1 1
ш1affectedrelatives 1.92(1.911.93)  1.91(1.891.93)
Multivariate ?adjustedmodel
Affectedrelativesofgout   
Norelativeaffected 1  1
ш1affectedrelatives 1.91(1.901.93) 1.97(1.941.99)
Placeofresidence   
Urban 1  1
Suburban 1.00(1.001.01) 1.05(1.041.05)
Rural 1.03(1.021.04)  1.10(1.091.12)
Aboriginal 1.34(1.331.36)  1.58(1.551.61)
Incomelevels   
Quartile1 1 1
Quartile2 1.14(1.131.16)  1.03(1.021.05)
Quartile3 0.98(0.970.99)  1.05(1.031.07)
Quartile4 1.10(1.091.11) 0.95(0.940.97)
Occupation   
Dependent 1  1
Civil servants, teachers and military
servicemen 1.14(1.131.16)  0.64(0.620.66)
Non ?manualworkersandprofessionals(%) 0.98(0.970.99)  0.73(0.720.74)













































































































environmental factors in the aetiologyof gout. The findings are consistentwith the relative
paucityofgoutsusceptibilitygenesidentifiedbygenome ?wideassociationstudiesincomparison

















opposite ?sex twins. Although lack of information on zygosity prevented the calculation of
heritabilitybasedon twindata, thehigherRRsharedbysame ?sex (partlymonozygotic) twins










effect of oestrogen which results in lower serum urate levels in premenopausal
women.(Adamopoulos et al., 1977) Therefore, prevalence of gout is generally low in




shows that familial transmission and heritability are both significantly higher inmen. These









and their independent contributions to the riskofgout couldnotbeexamined.Further, the
analysisof relative genetic andenvironmental contributionswasbasedon themultifactorial
liabilitymodelandtheresultsaresubjecttoassumptionssoshouldbeinterpretedwithcaution.
However, thepublisheddataonotherdisease such as schizophrenia (Wray andGottesman,
2012)support thevalidityof thismodel.Finally itwasnotpossible toexamine theeffectsof
assortativemating,wherebyspousesaremoresimilar foraphenotype than theywouldbe if













anentirepopulationofTaiwan.The resultsof this study confirm theclinicalbelief thatgout
clusterswithinfamiliesandthatbothgeneticandenvironmentalcomponentscontributetoits









Current clinical guidelines and recommendations endorsed by the European League against
Rheumatism(EULAR),(Zhangetal.,2006a)AmericanCollegeofRheumatology(ACR)(Khannaet
al., 2012a) and British Society of Rheumatology (BSR)(Jordan et al., 2007) agree on the
importanceofcomorbidityongoutmanagementbutonlydiscussdiseasesthatarerecognised








etal.,2008,Richetteetal.,2013)For instance,a recent large study found thatonly12%of
prevalent cases were considered to be isolated gout without significant associated
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comorbidities.(Richette et al., 2013) However, previous studies have only included limited
categoriesofcomorbiditiesandhavenotexaminedthetimingofcomorbidityoccurrencerelative
togoutdiagnosis. Ifmanyormostgoutpatientssuffercomorbidityatdiagnosisand the risk
continues to increase afterwards, current management paradigms should be changed, for



















at least a three ?year registrationprior to the indexdate.(Cea Soriano et al.,2011) The case
definitionwas based on physician ?diagnosis using 18 Read codes indicative of incident gout













one year prior to diagnosis and one from diagnosis to the earliest date of occurrence of
comorbidity,death, transferoutorendof study (31December2013),whichever came first.







Goutwasdefinedasthe indexdisease inthisstudyandFeinsteinsdefinitionwasutilised for
comorbidity,specificallyAnydistinctadditionalentitythathasexistedormayoccurduringthe
clinicalcourseofapatientwhohasthe indexdiseaseunderstudy.(Feinstein,1970) General
health statuswasmeasured by the Charlson co ?morbidity index. This index summarises 17
diagnostic categories (myocardial infarction, congestive heart failure, peripheral vascular
disease,cerebrovasculardisease,dementia,chronicpulmonarydisease,rheumatologicdisease,
pepticulcerdisease,mildliverdisease,moderateorsevereliverdisease,diabetesmellitus[DM],
DM with chronic complications, renal diseases, any malignancy [including leukaemia and
lymphoma],metastatic solid tumour and human immunodeficiency virus [HIV] infection) to
representoneshealthstatusandhasbeenshowntobeausefulpredictorformortality.(Charlson
etal.,1994)DeyoetalproducedavalidatedversionforusewiththeICD ?9baseddatabase,(Deyo
et al., 1992)whichwas the basis of the validated Read code version.(Khan et al., 2010b) I
calculatedtheCharlsonscoreforeachstudypersonatbaselinebyaddingscoresassignedtoeach
specificdiagnosis.Inaddition,othercomorbiditieswereincorporated,includinganaemia,cardiac




conditions were also based on physician diagnosis recorded as Read codes. The Charlson
comorbidityindexwascategorisedas(1)0,1 ?2,3 ?4andш5scoresand(2)0andш1score.
Mortality was based on the recording in themain database. The CPRD has developed an
algorithmtoidentifydeathanddateofdeathfordeceasedparticipants.Inordertovalidatethe
recordeddeathanddeathdateinCPRD,datawererequestedfromthedeathregistrationfrom




thesepractices.Of these,209,154participantswere identifiedasdeceasedby theCPRDbut













CPRD recorded Not recorded
Recorded 195,047 14,107 209,154 93.3% 
Not recorded 2,092 3,311,355 3,313,447  99.9%
Total 197,139 3,325,462 3,522,601  
Sensitivity 98.94% 
Specificity  99.6%   











plots were used to estimate the cumulative probability of each comorbidity and all ?cause
mortality for peoplewith incident gout and thosewithout.Only people at risk for a given
comorbiditywereconsideredfortheprospectiveanalysis. Hazardratio(HR)and95%CIwere
calculated formortality byCox proportional hazardsmodel. TheHRswere adjusted by age,








14.5 years and approximately three quarters beingmen. Theywere 1:1matched to 31,138
controlswiththesameageandsexstructure(Table7 ?2).Theoddsofdevelopinggoutincreased









odds ratios (95% CI)
Adjusted
odds ratios (95% CI)a
Age (years)    
<50 years 7,560 (24.28) 7,581 (24.35) NA NA
50-59 years 6,842 (21.97) 6,891 (22.13) NA NA
60-69 years 7,194 (23.10) 7,135 (22.91) NA NA
70 years 9,542 (30.64) 9,531 (30.61) NA NA
Gender    
Men 22,803 (73.23) 22,803 (73.23) NA NA
Women 8,335 (26.77) 8,335 (26.77) NA NA
BMI (kg/m2)    
<18.5 171 (0.55) 427 (1.37) 0.63 (0.53௅0.76) 0.62 (0.52௅0.75)
18.5  24.9 6,013 (19.31) 9,505 (30.53) Reference Reference
25.0  29.9 12,474 (40.06) 10,624 (34.12) 1.86 (1.78௅1.93) 1.88 (1.80௅2.00)
30 10,385 (33.35) 5,247 (16.85) 3.13 (2.99௅3.28) 3.20 (3.05௅3.35)
Unknown  2,095 (6.73) 5,335 (17.13) 0.62 (0.59௅0.66) 0.62 (0.58௅0.66)
Smoking    
Non-smoker 8,454 (23.01) 7,165 (23.01) Reference Reference
Current smoker 4,517 (14.51) 3,402 (10.93) 1.13 (1.07௅1.19) 1.14 (1.08௅1.20)
Ex-smoker 14,331 (46.02) 13,665 (43.89) 0.90 (0.86௅0.92) 0.85 (0.82௅0.89)
Unknown 3,836 (12.32) 6,906 (22.18) 0.47 (0.45௅0.50) 0.45 (0.43௅0.47)
Alcohol consumption (units/week)    
Never/ Ex-drinker 2,951 (9.48) 3,307 (10.62) Reference Reference
Current 1-9  13,776 (13776) 13,872 (44.55) 1.11 (1.05௅18) 1.15 (1.09௅1.21)
Current 10 8,551 (27.46) 4,712 (15.13) 2.03 (1.91௅2.16) 2.17 (2.04௅2.31)
Unknown 5,860 (18.82) 9,247 (29.70) 0.71 (0.70௅0.75) 0.74 (0.70௅0.79)












As shown in Table 7 ?3, all diseases in the cardiovascular and genitourinary systems were
associatedwith a higher risk of incident gout. Among them, renal diseases (OR, 5.41) and
congestiveheartdisease(OR,3.99)wereassociatedwiththegreatestriskof incidentgout. In
addition, solidmalignancy, leukaemia and lymphoma (OR 1.21), hyperlipidaemia (OR 1.74),
hypothyroidism(OR1.42),chronicpulmonarydiseases(OR1.23),osteoarthritis(oddsratio1.20),
anaemia (odds ratio1.32)andpsoriasis (oddsratio1.22)werealsopositivelyassociatedwith
incidentgoutinadjustedmodelsinboththe10 ?yearandone ?yearperiods,whileonlymultiple









 10 year period before index date  1 year period before index date
 Cases Controls Unadjusted OR Adjusted ORa  Cases Controls Unadjusted OR Adjusted ORa
Charlson comorbidity index categories         
0 20,597 (66.15) 23,382 (75.09) Reference Reference  26,414 (84.83) 27,888 (89.56) Reference Reference
1-2 8,436 (27.09) 6,536 (20.99) 1.55 (1.47௅1.63)* 1.29 (1.22௅1.36)*  4,318 (13.87) 3,024 (9.71) 1.54 (1.48௅1.60)* 1.34 (1.28௅1.40)*
3-4 1,680 (5.40) 1,008 (3.24) 1.94 (1.63௅2.31)* 1.53 (1.27௅1.85)*  365 (1.17) 206 (0.66) 2.07 (1.90௅2.25)* 1.72 (1.57௅1.88)*
5 425 (1.36) 212 (0.68) 2.28 (1.33௅3.90)* 2.01 (1.11௅3.61)*  41 (0.13) 20 (0.06) 2.56 (1.16௅3.03)* 1.99 (1.66௅3.39)*
Neoplasms         
Solid malignancy,  leukemia and lymphoma 1,391 (4.47) 1,127 (3.62) 1.25 (1.15௅1.36)* 1.21 (1.10௅1.32)*  351 (1.13) 272 (0.87) 1.30 (1.11௅1.52)* 1.26 (1.06௅1.49)*
Metastatic solid tumors 22 (0.07) 21 (0.07) 1.08 (0.58௅1.91) 1.00 (0.52௅1.92)  4 (0.01) 8 (0.03) 0.50 (0.15௅1.66) 0.70 (0.87௅2.68)
Circulatory system         
Hypertension 10,820 (34.75) 5,563 (17.87) 2.78 (2.67௅2.90)* 2.17 (2.07௅2.27)*  4,229 (13.58) 2,107 (6.77) 2.35 (2.21௅2.49)* 1.83 (1.72௅1.95)*
Cardiac arrhythmias 2,200 (7.07) 938 (3.01) 2.58 (2.38௅2.80)* 2.47 (2.27௅2.62)*  637 (2.05) 259 (0.83) 2.54 (2.19௅2.94)* 2.28 (1.95௅2.67)*
Cerebrovascular disease 1,471 (4.72) 960 (3.08) 1.58 (1.45௅1.72)* 1.43 (1.31௅1.57)*  323 (1.04) 209 (0.67) 1.56 (1.31௅1.86)* 1.39 (1.15௅1.68)*
Congestive heart failure 1,709 (5.49) 458 (1.47) 4.38 (3.91௅4.91)* 3.99 (3.54௅4.49)*  482 (1.55) 118 (0.38) 4.43 (3.59௅5.47)* 4.00 (3.20௅5.00)*
Myocardial infarction 1,420 (4.56) 726 (2.33) 2.04 (1.86௅2.24)* 1.79 (1.62௅1.98)*  183 (0.59) 120 (0.39) 1.53 (1.22௅1.93)* 1.34 (1.04௅1.73)*
Peripheral vascular disease 921 (2.96) 583 (1.87) 1.62 (1.46௅1.81)* 1.51 (1.34௅1.69)*  211 (0.68) 124 (0.40) 1.72 (1.37௅2.15)* 1.55 (1.22௅1.98)*
Valvular heart disease 559 (1.80) 230 (0.74) 2.50 (2.13௅2.92)* 2.50 (2.11௅2.95)*  132 (0.42) 45 (0.14) 3.02 (2.14௅4.27)* 2.63 (1.82௅3.80)*
Genitourinary systems         
Urolithiasis 295 (0.95) 224 (0.72) 1.32 (1.10௅1.57)* 1.22 (1.01௅1.48)*  59 (0.19) 34 (0.11) 1.74 (1.14௅2.65)* 1.74 (1.09௅2.76)*
Renal diseases 715 (2.30) 133 (0.43) 5.51 (4.57௅6.65)* 5.41 (4.44௅6.58)*  302 (0.97) 42 (0.13) 7.34 (5.30௅10.17)* 7.50 (5.33௅10.55)*
Metabolic/endocrine disease         
Uncomplicated diabetes mellitus 1,926 (6.19) 1,631 (5.24) 1.20 (1.12௅1.28)* 0.87 (0.81௅0.94)*  1,275 (4.09) 1,011 (3.25) 1.28 (1.18௅1.40)* 0.91 (0.83௅1.00)
Diabetes mellitus with complications 329 (1.06) 319 (1.02) 1.03 (0.88௅1.21) 0.77 (0.65௅0.92)*  141 (0.45) 126 (0.40) 1.12 (0.88௅1.43) 0.80 (0.62௅1.04)
Hyperlipidaemia 3,172 (10.19) 1,676 (5.38) 2.10 (1.87௅2.24)* 1.74 (1.62௅1.87)*  805 (2.59) 391 (1.26) 2.15(1.90௅2.44)* 1.88 (1.65௅2.16)*
Hypothyroidism 1,045 (3.36) 669 (2.15) 1.61 (1.46௅1.78)* 1.42 (1.27௅1.58)*  273 (0.88) 163 (0.52) 1.69 (1.39௅2.06)* 1.51 (1.22௅1.87)*
Gastrointestinal and hepatic diseases         
Peptic ulcer disease 577 (1.85) 522 (1.68) 1.11 (0.98௅1.25)* 1.08 (0.95௅1.23)  60 (0.19) 43 (0.14) 1.11 (0.98௅1.25) 1.08 (0.95௅1.23)
Mild liver disease 115 (0.37) 68 (0.22) 1.69 (1.25௅2.28)* 1.41 (1.02௅1.96)*  29 (0.09) 15 (0.05) 1.69 (1.25௅2.28)* 1.41 (1.02௅1.96)*
Moderate to severe liver disease 22 (0.07) 20 (0.06) 1.10 (0.60௅2.02)* 1.05 (0.56௅2.00)  5 (0.02) 7 (0.02) 1.10 (0.60௅2.02) 1.05 (0.56௅2.00)
Chronic pulmonary diseases 3,830 (12.30) 2,886 (9.27) 1.39 (1.32௅1.46)* 1.23 (1.16௅1.30)*  1,708 (5.49) 1,201 (3.86) 1.39 (1.32௅1.46)* 1.23 (1.16௅1.30)*
Musculoskeletal & connective tissue diseases         
Osteoarthritis 3,184 (10.23) 2,337 (7.51) 1.46 (1.37௅1.55)* 1.20 (1.13௅1.28)*  771 (2.48) 490 (1.57) 1.61 (1.43௅1.80)* 1.35 (1.19௅1.54)*
Rheumatologic disease 1,981 (6.36) 1,751 (5.62) 1.15 (1.07௅1.23)* 0.92 (0.86௅0.99)*  909 (2.92) 740 (2.38) 1.25 (1.13௅1.38)* 0.95 (0.85௅1.06)
Neurological and mental disorders         
Dementia 37 (0.12) 74 (0.24) 0.50 (0.34௅0.74)* 0.56 (0.37௅0.86)*  13 (0.04) 29 (0.09) 0.45 (0.23௅0.86)* 0.56 (0.28௅1.13)
Hemiplegia 101 (0.32) 83 (0.27) 1.22 (0.91௅1.63) 1.19 (0.86௅1.64)  16 (0.05) 14 (0.04) 1.14 (0.56௅2.34) 1.05 (0.48௅2.31)
Multiple sclerosis 27 (0.09) 51 (0.16) 0.53 (0.33௅0.84)* 0.53 (0.32௅0.88)*  6 (0.02) 18 (0.06) 0.33 (0.13௅0.84)* 0.26 (0.10௅0.69)*
Other neurological diseases 482 (1.55) 566 (1.82) 0.85 (0.75௅0.96)* 0.84 (0.74௅0.96)*  117 (0.38) 146 (0.47) 0.80 (0.63௅1.02) 0.84 (0.65௅1.10)
Psychosis 100 (0.32) 143 (0.46) 0.70 (0.54௅0.90)* 0.70 (0.53௅0.92)*  23 (0.07) 26 (0.08) 0.89 (0.51௅1.55) 0.90 (0.49௅1.65)
Depression 3,680 (11.82) 3,135 (10.07) 1.21 (1.15௅1.27)* 1.12 (1.06௅1.18)*  919 (2.95) 745 (2.39) 1.24 (1.13௅1.37) 1.12 (1.00௅1.25)
Other comorbidities         
Anaemia 2,608 (8.38) 1,786 (5.74) 1.54 (1.45௅1.65)* 1.32 (1.23௅1.41)*  503 (1.62) 286 (0.92) 1.80 (1.55௅2.09)* 1.58 (1.34௅1.85)*
Psoriasis 1,002 (3.22) 728 (2.34) 1.39 (1.26௅1.53)* 1.22 (1.09௅1.35)*  288 (0.92) 178 (0.57) 1.63 (1.35௅1.97)* 1.48 (1.20௅1.81)*
HIV infection 7 (0.02) 3 (0.01) 2.33 (0.60௅9.02) 1.42 (0.29௅6.82)  2 (<0.01) 1 (<0.01) 2.00 (0.18௅22.05) 0.90 (0.07௅11.09)





5.53%) and 18.49% (18.01%വ18.97%) respectively in incident gout patients, comparedwith













   Cases   Controls
  At diagnosis 1 year 2 years 5 year 10 year At diagnosis 1 year 2 years 5 year 10 year
Charlson comorbidity index >0  33.85 37.43 40.51 49.50 62.84 24.91 27.24 29.64 37.20 48.74
Any increase in Charlson comorbidity index  0 3.57 6.66 15.46 26.05  0 2.33 4.73 12.09 21.01
Neoplasms   
Solid malignancy,  leukemia and lymphoma  4.47 5.20 6.09 9.80 17.39 3.62 4.19 4.93 8.42 15.21
Metastatic solid tumors  0.07 0.09 0.13 0.52 1.48  0.07 0.08 0.11 0.50 1.49
Circulatory system   
Hypertension  34.75 38.41 41.57 49.59 59.57  17.87 20.29 22.89 29.95 38.71
Cardiac arrhythmias  7.07 8.02 8.95 11.88 16.94 3.01 3.46 4.10 6.10 9.62
Cerebrovascular disease  4.72 5.46 6.16 8.58 12.62 3.08 3.63 4.20 61.3 9.48
Congestive heart failure  5.49 6.04 6.63 8.25 10.84  1.47 1.73 1.99 3.08 4.87
Myocardial infarction  4.56 4.98 5.33 6.72 9.08 2.33 2.61 2.89 4.04 5.71
Peripheral vascular disease  2.96 3.41 3.80 5.03 7.10  1.87 2.16 2.44 3.31 4.80
Valvular heart disease  1.80 2.07 2.38 3.34 5.05 0.74 0.88 1.04 1.60 2.79
Genitourinary system            
Urolithiasis  0.95 1.04 1.13 1.42 1.99 0.72 0.81 0.89 1.11 1.48
Renal diseases  2.30 3.02 3.88 6.93 10.78 0.43 0.56 0.76 1.67 3.32
Metabolic/endocrine disease            
Uncomplicated diabetes mellitus  6.19 7.48 8.75 13.00 20.05 5.24 5.92 6.63 8.70 12.27
Diabetes mellitus with complications  1.06 1.33 1.68 3.27 13.57  1.02 1.26 1.57 2.67 8.67
Hyperlipidaemia  10.19 11.86 13.34 17.22 22.16 5.38 6.32 7.27 10.04 13.78
Hypothyroidism  3.36 3.85 4.35 5.88 7.92 2.15 2.43 2.79 3.97 5.40
Digestive system            
Peptic ulcer disease  1.85 2.10 2.27 2.77 3.54 1.68 1.81 1.94 2.25 2.85
Mild liver disease  0.37 0.47 0.58 1.07 1.96  0.22 0.27 0.32 0.49 0.94
Moderate to severe liver disease  0.07 0.08 0.09 0.19 0.42 0.066 0.08 0.09 0.16 0.33
Chronic pulmonary diseases  12.30 13.32 14.19 16.73 20.62  9.27 10.00 10.68 12.76 16.30
Musculoskeletal & connective tissue diseases   
Osteoarthritis  10.23 11.96 13.50 17.54 23.27 7.51 8.39 9.25 12.01 15.86
Rheumatologic disease  6.36 7.62 8.82 12.06 17.89  5.62 6.35 7.06 8.93 12.02
Nervous system and mental disorders   
Dementia  0.12 0.20 0.32 0.89 2.52  0.24 0.32 0.50 1.31 2.97
Hemiplegia  0.32 0.40 0.45 0.6 0.92 0.27 0.31 0.34 0.47 0.66
Multiple sclerosis  0.08 0.10 - 0.12 0.4 0.16 0.18 0.19 2.03 2.49
Other neurological diseases  1.55 1.84 2.14 3.18 4.84  1.82 2.09 2.42 3.39 5.04
Psychosis  0.32 0.39 0.43 0.62 1.03 0.46 0.50 0.55 0.76 1.15
Depression  11.82 13.13 14.40 18.24 24.05  10.07 11.16 12.26 15.34 20.14
Other comorbidities   
Anaemia  7.97 9.26 10.42 14.63 21.88  5.57 6.28 7.02 9.96 14.76
Psoriasis  3.22 3.55 3.84 4.67 5.86 2.34 2.60 2.86 3.41 4.12
HIV infection  0.02 0..03 0.04 0.04 - <0.001 - - 0.02 -









attempted toexaminea fullrangeofcomorbidities including thosenot listed in theCharlson
comorbidityindex.Theprevalenceofhypertension,cardiacarrhythmias,valvularheartdisease,
urolithiasis, hyperlipidaemia, hypothyroidism, chronic pulmonary disease, osteoarthritis,
depression,anaemiaandpsoriasiswereall significantlyhigher in incidentgoutpatients than
controls.Despiteotherdiseaseswhichaffectlongevity,goutitselfcausesanadditional11%of
deathsintheUKgeneralpopulation.Overall,theburdenofcomorbidityisveryhighatdiagnosis
ofgoutand the riskofall ?causemortality isalsohigher in incidentgoutpatients than in the
generalpopulationindependentofcomorbiditiesatdiagnosis.
Therelationshipsbetweenindexdiseaseandcomorbidityareverycomplex(Valderasetal.,2009)
butbroadly canbe classified into threemodels:direct causation,associated risk factorsand
heterogeneity.(Rheeetal.,2004)Theassociationbetweengoutandmetabolicsyndrome,(Choi




between gout and metabolic syndrome were not measured directly, there were close
relationships between gout and the individual metabolic syndrome components such as
hypertension,hyperlipidaemiaandobesity (increasedBMI).The coexistenceofgoutand the
components of metabolic syndrome probably is the result of the close links between





















found that uric acid concentration in synovial fluid strongly correlates with synovial
concentrationofpro ?inflammatorycytokines(suchasinterleukins1and18)andisamarkerfor






to reversehyperuricaemia secondary tohypothyroidism.(Giordanoet al.,2001,Mooraki and
Bastani, 1998) Furthermore reduced glomerular filtration rate is reduced in patients with
hypothyroidism(MarianiandBerns,2012)suggestingan influenceofthyroxineonrenalurate
clearance.(MarianiandBerns,2012)Anotherexampleisanaemia,whichwasfoundtobemore
prevalent in incident goutpatients in this study, as itwas in theAtherosclerosisRisk in the








Despite the complexity of aetiological associations, clinical implications of comorbidity are
simple.Wecouldregardcomorbidityaspartofthediagnosticprocess,asaconsideration for
managementdecisionsandasa flagforprognosis.(Feinstein,1970)Giventhatthere isagold






and requires special attention in managing gout patients. Currently, EULAR
recommendations,(Zhangetal.,2006a)BSR(Jordanetal.,2007)andACRguidelines(Khannaet
al., 2012a) have considered comorbidity as part of initial assessment of gout patients and
generally advise clinicians to consider comorbidity thatmay contribute to,or associatewith




















high.(Meier and Jick, 1997)  Similarly there may have been some misclassification of
comorbidities, although againmost of the comorbidities in this study have been validated




between incident gout patients and controls cannot be excluded entirely, even though the
estimatesbasedondifferentlengthofpreviousobservationproducedsimilarresults.Third,the
modelsdidnotadjustforallpotentialriskfactorsforgoutyarthritis,suchasdietandphysical
activity,bothofwhicharenotroutinelyrecorded in theCPRD.However, thisstudyaimed to
provide estimates of disease burden of gout patients both at diagnosis and subsequent to
diagnosis,ratherthantodefinecausesofgout.Fourthly,theproblemassociatedwithmultiple
testingmayariseinthisstudy.However,themainfocusofthisanalysiswastoidentifyexposures
and outcomes that aremore closely associated with gout. Also,most of the results were
interpretedinthelightofexistingresearchsotheconclusionsareunlikelytohavebeenaffected
unduly by false positive findings. In addition, the sample size of this study is about 62,000
including cases and controls.  Evenwhen a Bonferroni correction is applied,which is very
conservativewhenthemultipleoutcomemeasuresunderconsiderationarenot independent,
themajorityofpreviouslysignificantresultsremainso.
In conclusion, themajorityofgoutpatients in theUKalreadyhave comorbidityat.All ?cause
mortalitywashigheringoutpatientsandtheincreasedriskwascontributedtobybothgoutitself







The prevalence of gout is rising worldwide(Roddy et al., 2007b) with a recent estimated
prevalenceof2.49%intheUK.(Kuoetal.,2013b)Thehallmarksofinitialgoutpresentationare
acutepain,swelling,erythemaandtenderness inperipheral jointsbuteventuallyunremitting
arthritis, joint deformity and tophus deposition may develop with long ?standing




1955, Durward, 1976, McAdams ?DeMarco et al., 2012) Collectively gout and associated









the first ?lineULT recommended by theNational Institute forHealth and Clinical Excellence, 
(Excellence, 2008) the European League against Rheumatism (EULAR) recommendations for

















The study was approved by the TrentMulti ?centre Research Ethics Committee (reference
number:05/MRE04/87) and the Independent ScientificAdvisoryCommittee (11 ?021R).  This
studywasapropensityscore ?matched landmarkstudycomparingall ?causemortalitybetween















Patients were classified by exposure to allopurinol. Aminimal of 6 ?months prescription of
allopurinolwasrequiredforassignmentofallopurinolexposure.Theprescriptionofallopurinol
asthe first ?lineULT,however, largely lagsbehind thetimeof firstdiagnosisand isgiventoa




































diagnostic categories (myocardial infarction, congestive heart failure, peripheral vascular
disease,cerebrovasculardisease,dementia,chronicpulmonarydisease,rheumatologicdisease,
pepticulcerdisease,mildliverdisease,moderateorsevereliverdisease,diabetesmellitus[DM],
DM with chronic complications, renal diseases, any malignancy [including leukaemia and
lymphoma],metastatic solid tumour and human immunodeficiency virus [HIV] infection) for
calculationoftheCharlsoncomorbidity index(Deyoetal.,1992,Khanetal.,2010b)andother
comorbidities (alcohol abuse, anaemia, cardiac arrhythmias, depression, drug abuse, hip
fracture, hypertension, hypothyroidism, multiple sclerosis, neurological diseases, psoriasis,
psychosis,urolithiasisandvalvularheartdisease).Thedefinitionsoftheseconditionswerealso
basedonphysiciandiagnosesrecordedasReadcodes.Thespecificcode listsareavailableon
request.Medicationsevaluated includeaspirin,anticoagulants,anticonvulsants, lipid lowering








Mortality and date of deathwere based on the recording in themain CPRD database. The
validation of all ?causemortality in CPRD compared with the ONS death registry has been
addressedinChapter7.
 Statisticalanalysis
Baselinecharacteristicsandevent rateswere summarized forallopurinolexposuregroupsas













covariates included were patient characteristics, life style factors, comorbidities and the
medications already listed. In the primary analysis the allopurinol exposed patients were
matchedtounexposedpatients inaratioof1to1basedonthe logitofthepropensityscore




























  Entire cohort
(n=23,332)
 One-year Landmark cohort Three-year landmark cohort














Age (years)     
Median (interquartile 
range)
 62 (50ʇ73)  62 (49ʇ73) 73 (60ʇ82) <0.001  61 (49ʇ71) 72 (58ʇ81) <0.001
Gender     
Men   17,197 
(73.71)
 16276 (74.16) 921 (66.50) <0.001  14628 (74.83) 2569 (67.91) <0.001
Women  6135 (26.29)  5671 (25.84) 464 (33.50) 4921 (25.17) 1214 (32.09)
BMI (kg/m2)          
<18.5  162 (0.69)  146 (0.67) 16 (1.16) <0.001 123 (0.63) 39 (1.03) <0.001
18.5  24.9  4975 (21.32)  4678 (21.31) 297 (21.44)   4142 (21.19) 833 (22.02) 
25.0  29.9  8910 (38.19)  8536 (38.89) 374 (27.00) 7846 (40.14) 1064 (28.13)
30  6119 (26.23)  5889 (26.83) 230 (16.61)   5466 (27.96) 653 (17.26) 
Unknown   3166 (13.57)  2698 (12.29) 468 (33.79) 1972 (10.09) 1194 (31.56)
Smoking          
Non-smoker  2688 (11.52)  2523 (11.50) 165 (11.91) 0.80 2307 (11.80) 381 (10.07) 0.03
Current smoker  1910 (8.19)  1804 (8.22) 106 (7.65)   1588 (8.12) 322 (8.51) 
Ex-smoker  13889 
(59.53)
 13059 (59.50) 830 (59.93)   11543 (59.05) 2346 (62.01) 
Unknown  4845 (20.77)  4561 (20.78) 284 (20.51) 4111 (21.03) 734 (19.40)
Alcohol consumption 
(units/week)
         
Never/ Ex-drinker  2525 (10.82)  2299 (10.48) 226 (16.32) 0.07 1992 (10.19) 533 (14.09) 0.35
Current 1-9   8957 (38.39)  8421 (38.37) 536 (38.70)   7461 (38.17) 1496 (39.55) 
Current 10  5496 (23.56)  5281 (24.06) 215 (15.52) 4799 (24.55) 697 (18.42)
Unknown  6354 (27.23)  5946 (27.09) 408 (29.46)   5297 (27.10) 1057 (27.94) 
Charlson comorbidity 
index
    
0  16211 
(69.48)
 15575 (70.97) 636 (45.92) <0.001  14365 (73.48) 1846 (48.80) <0.001
1-2  5916 (25.36)  5384 (24.53) 532 (38.41) 4476 (22.90) 1440 (38.07)
3-4  1141 (4.89)  947 (4.31) 194 (14.01)   687 (3.51) 454 (12.00) 
4  64 (0.27)  41 (0.19) 23 (1.66) 21 (0.11) 43 (1.14)
Medications          
Aspirin  4188 (17.95)  3750 (17.09) 438 (31.62) <0.001 3047 (15.59) 1141 (30.16) <0.001
Statin  105 (4.52)  986 (4.49) 69 (4.98) 0.40)  883 (4.52) 172 (4.55) 0.94
Diuretics  8878 (38.05)  8023 (36.56) 855 (61.73) <0.001)  6687 (34.21) 2191 (57.92) <0.001
Insulin  122 (0.52)  103 (0.47) 19 (1.37) <0.001) 84 (0.43) 38 (1.00) <0.001
NSAID  17024 
(72.96)





















from initial diagnosis of gout before and after matching. Values are numbers
(percentage)unlessdescribedotherwise.
 Exposure groups before matching Exposure groups after matching
















Age (years)        
Median (interquartile 
range)
 66 (56ʇ74) 61 (49ʇ73) <0.001  66 (55ʇ75) 66 (56ʇ74) 0.87
Gender        
Men   665 (65.45) 15611 (74.58) <0.001  665 (65.45) 655 (64.47) 0.64
Women  351 (34.55) 5320 (25.42)   351 (34.55) 361 (35.53) 
BMI (kg/m2)        
<18.5  2 (0.20) 144 (0.69) <0.001  2 (0.20) 2 (0.20) 0.89
18.5  24.9  206 (20.28) 4472 (21.37)   206 (20.28) 223 (21.95) 
25.0  29.9 375 (36.97) 8161 (38.99) 375 (36.97) 351 (34.55)
30 352 (34.65) 5537 (26.45) 352 (34.65) 357 (35.14)
Unknown  81 (7.97) 2617 (12.50 81 (7.97) 83 (8.17)
Smoking        
Non-smoker  132 (12.99) 2391 (11.42) <0.001  132 (12.99) 135 (13.29( 0.72
Current smoker  96 (9.45) 1708 (8.16)   96 (9.45) 112 (11.02) 
Ex-smoker  638 (62.80) 12421( 59.34)   638 (62.80) 613 (60.33) 
Unknown  150 (14.76 4411 (21.07)   150 (14.76 156 (15.35) 
Alcohol consumption 
(units/week)
       
Never/ Ex-drinker  158 (15.55) 2141 (10.23) <0.001  158 (15.55) 167 (16.44) 0.80
Current 1-9   435 (42.81) 7986 (38.15)   435 (42.81) 444 (43.70) 
Current 10  211 (20.77) 5070 (24.22)   211 (20.77) 188 (18.50) 
Unknown  212 (20.87) 5734 (27.39)   212 (20.87) 217 (21.36) 
Charlson comorbidity 
index
       
0  600 (59.06) 14975 (71.54) <0.001  600 (59.06) 591 (58.17) 0.84
1-2  330 (32.48) 5054 (24.15)   330 (32.48) 341 (33.56) 
3-4  82 (8.07) 865 (4.13)   82 (8.07) 81 (7.97) 
4  4 (0.39) 37 (0.18)   4 (0.39) 3 (0.30) 
Medications        
Aspirin  295 (29.04) 3455 (16.51) <0.001  295 (29.04) 296 (29.13) 0.96
Statin  94 (9.25) 892 (4.23) <0.001  94 (9.25) 86 (8.46) 0.53
Diuretics  622 (61.22) 7401 (35.36) <0.001  622 (61.22) 617 (60.73) 0.82
Insulin  10 (0.98) 93 (0.44) 0.01  10 (0.98) 15 (1.48) 0.31




from initial diagnosis of gout before and after matching. Values are numbers
(percentage)unlessdescribedotherwise.
  Exposure groups before matching Exposure groups after matching
















Age (years)   
Median (interquartile 
range)
 64 (52ʇ73) 60 (48ʇ71) <0.001 64 (52ʇ73) 63 (51ʇ73) 0.69
Gender   
Men   2530 (71.90) 12085 (75.49) <0.001 2530 (71.90) 2542 (72.24) 0.75
Women  989 (28.10) 3924 (24.51) 989 (28.10) 977 (27.76)
BMI (kg/m2)   
<18.5  14 (0.40) 109 (0.68) 0.009 14 (0.40) 16 (0.5) 0.93
18.5  24.9  633 (17.99) 3508 (21.91) 633 (17.99) 642 (18.24)
25.0  29.9  1357 (38.56) 6482 (40.49) 1357 (38.56) 1351 (38.39)
30  1205 (34.24) 4248 (26.54) 1205 (34.24) 1202 (34.16)
Unknown   310 (8.81) 1662 (10.38) 310 (8.81) 308 (8.78)
Smoking   
Non-smoker  427 (12.13) 1877 (11.72) 0.006 427 (12.13) 426 (12.11) 0.93
Current smoker  273 (7.716) 1312 (8.21) 273 (7.716) 290 (8.24)
Ex-smoker  2136 (60.70) 9392 (58.62) 2136 (60.70) 2117 (60.16)





Never/ Ex-drinker  419 (11.91) 1567 (9.79) 0.004 419 (11.91) 425 (12.08) 0.79
Current 1-9   1391 (39.53) 6058 (37.84) 1391 (39.53) 1369 (38.90)
Current 10  820 (23.30) 3979 (24.85) 820 (23.30) 846 (24.04)




0  2330 (66.82) 12035 (75.18) <0.001 2329 (66.18) 2341 (66.52) 0.75
1-2  1017 (28.73) 3459 (21.61) 1008 (28.64) 999 (28.39)
3-4  187 (5.28) 500 (3.12) 176 (5.00) 174 (4.49)
4  6 (0.17) 15 (0.09) 6 (0.17) 5 (0.14)
Medications   
Aspirin  799 (22.57) 2248 (14.04) <0.001 785 (22.31) 796 (22.62) 0.75
Statin  263 (7.43) 620 (3.87) <0.001 255 (7.25) 248 (7.05) 0.75
Diuretics  1778 (50.23) 4909 (30.66) <0.001 1757 (49.93) 1778 (50.53) 0.62
Insulin  18 (0.51) 66 (0.41) 0.43 18 (0.51) 14 (0.40) 0.48

























Figure 8 ?2 Kaplan ?Meier survival plot for all ?causemortality in (a) one ?year and (b)






Similar results to themain analysis were obtained when propensity score adjustment was
undertakenforallincludedpatients inboththeone ?yearandthree ?year landmarkanalysis.In
theone ?yearlandmarkanalysis,allopurinolwasassociatedwithanunadjustedhazardratio(95%
confidence interval)of1.49 (1.32ʇ1.67) and apropensity score adjustedhazard ratio (95%
confidence intervalof1.02(0.95ʇ1.09)forall ?causemortality. Inthethree ?yearanalysis,the







months use of allopurinolwithin either one year or three years from initial diagnosiswas
associatedwithneitherabeneficialnoradverseeffectonlong ?termriskofall ?causemortalityin
patientswhosurvivedtothedateofthelandmarktimepoint.Thisstudyconfirmsthatconcern






In this studyawell ?definedpopulationof incidentgoutpatientswasexamined todetermine
whetherallopurinoltreatmentinfluencesall ?causemortality.Thisstudyisanobservationstudy
basedonprimarycaredatainwhichthedateofallopurinolprescriptionlargelylagsbehindthe
initial diagnosis of gout,with approximately one in four being treatedwithin 12months of
diagnosis.(Chapters5and6;(Kuoetal.,2013a)Usingdiagnosisdateasanindexdatetostartthe
followupforadelayedtreatmentinacohortstudyispronetoimmortaltimebias.(Weissetal.,
1983)  Immortal time isdefinedasaperiodof follow ?up inwhich thestudyoutcomecannot
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model or a landmark analysis as in this study.(Dafni, 2011)With prior knowledge that the
cumulativeprobabilitiesforULTprescriptioninUKprimarycarewere16.90%,21.14%,24.52%
and30.39%at0,1,2,3and5yearsfromdiagnosis(unpublisheddatafromChapter6),itwas
determined a priori that an exposure window of three years could capture over 80% of
allopurinoluserstopreventmisclassificationatlongertermfollow ?up.However,becauseofthe
landmarkanalysisdesignpatientswhodiedwithintheexposurewindowwerenotconsideredin















allopurinol exposure group. Propensity scorematching to balance the probability of being
prescribedallopurinolintheexposurewindowwasusedtominimisethisbias.Propensityscore
adjustment,asasinglevariable,wasalsousedfortheentirepopulationtoexamineriskofdeath
between patients exposed and unexposed to allopurinol. Analyses based on bothmethods





2009, Luket al.,2009, Strutherset al.,2002,Dubreuilet al.,2014)These studies in general
ignoredoronlyinpartconsideredimmortaltimebiasandconfoundingbyindication.Immortal
timebiasgenerallycausesspuriousinflationofbeneficialtreatmenteffectduetotheguaranteed











et al. reported that allopurinolusewas associatedwith abeneficialeffectonmortality in a
hyperuricaemic population by comparing survival between users and non ?users. However,
allopurinoluserscommencedfollow ?upfromthetimeofincidentallopurinoluse(indexdate),at
whichtimetheyhadsurvivedfromthedateoffirstdocumentationofhyperuricaemia,whereas
the follow ?up of non ?users could have been as early as the date of first documentation of
hyperuricaemia.Althoughtheymatchedtheindexdatebetweenusersandnon ?users,itdidnot
mean that theymatched the time from the diagnosis of hyperuricaemia to the index date









approach to randomly select a date from the same accrual block (6months per block) to
approximatelymatchtheindexdatebetweenusersandnon ?users.Again,thetimetotheindex
datewasnotmatchedandtheimmortaltimeperiodismorelikelytobelongerintheusergroup
due to thedelayedallopurinolprescription.  In sucha situation, theallopurinolusershavea
survivaladvantagewhichhasnothing todowith theallopurinolexposure.Thereforewithout
tacklingimmortaltimebiasbydesign(suchasusinglandmarkanalysis)orexplicitlymodellingthe
timing of exposure (such as using time dependentmethods) biased estimate can inevitably
occur.(Beyersmannetal.,2008)Thisisaverycommonbiasincohortstudies.Forexample,the
finding suggested 4 ?year survival advantage for Oscar winners over their less recognised
peers(RedelmeierandSingh,2001)waslargelyduetoimmortaltimebiasandthattherewasno
statistical difference between winners and their peers once this bias was taken into
consideration.(Sylvestreetal.,2006)Inordertocontrolimmortaltimebiasinthecurrentstudy
alandmarkanalysiswasundertakenwhichbydesignimplementedafixedexposurewindowfor
bothallopurinolusersandnon ?usersand thereforeavoided inadvertent survivalbenefits for
allopurinol users.(Dafni, 2011) The use of landmark analysis and propensity scores helped

































This thesis focusedon theepidemiologyofgout in theUKandTaiwan.Basedon two
nationallyrepresentativedatabases,sixdifferentstudieswereconductedtounderstand



















Bothprevalenceand incidencearehigher inTaiwanthan intheUK.Although it isvery
difficulttocompareprevalencebetweencountriesdirectly,thisthesistriestousesimilar


















reducingafter the ageof80 years. There isno significant rise in goutprevalence in
womenuntil50 yearsofage, coincidingwith theageof themenopause. Inmen the
prevalenceofgoutincreasedlinearlywithageuntiltheageof80years.Thispatternis






UK. Several potential factors may account for the obvious differences in gout
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epidemiology.Firstly, theethniccomposition isclearlydifferent.TheUKpopulation is
primarilycomposedofEuropeandescendantsandtheTaiwanpopulationisamixtureof
HanChinesedescendantsand indigenouspeoplewhoaregenetically related togout ?
laden Pacific Islanders. Secondly, Taiwan has become increasingly socioeconomically
westernised inrecentyears, includingmarkedchanges indiet,whichcouldexplainthe
lower prevalence of gout in the 1990s than estimates in the 2000s. Therefore, an














unevendistributionofgout reflect the regionaldifferences inbothgenetic/racialand
environmentalfactors.AssuggestedinChapter3,bothgeneticandenvironmentalfactors
contributetothevariationingoutoccurrenceatapopulationlevelsbutgeneticfactors
account for less than one ?third of such variations. Previous genetic studies have
documentedthatthedifference insusceptibilitytogout ispartlycontrolledbygenetic
differences. For instance, genetic variation in the ABCG2 gene, encoding a uric acid








Inaddition, theprevalenceand incidenceofalcoholismwere veryhigh in indigenous
peopleinTaiwan,(ChengandChen,1995,Leeetal.,2013,ChenandCheng,1997)which















rather than strategic (Chapter 6) strategies focusing onmore activeGP education to
improve interest and quality of gout patient care seem appropriate. One of the
practitionerbarrierstooptimalgoutmanagementthroughuseofULTistheconcernover
rarebutpotentiallyseriousadversedrugreactionassociatedwithallopurinol.However,













comorbidities. NSAIDs for instance, should be avoided in patients with peptic
ulcers,(Lanas,2010)renal(Goochetal.,2007)andcardiovasculardiseases(Trelleetal.,










A comprehensive screening for comorbidities at diagnosis in gout patients seem
warranted. It should be noted that themajority of gout patients have one ormore
comorbiditiesatdiagnosis.Therefore,treatmentdecisionsshouldbebasednot juston
thestatusofthepatientsgoutbutalsoonthepresenceofcomorbidities.
This thesis explored the utility of the CPRD and NHIRD for research into gout and




andmyocardial infarction audit (MINAP).More detailed research on the associations
betweengoutandcancerormyocardialinfarctioncanbeperformedusingtheselinkages.












provide better information on the validity of the entered diagnosis of gout in these
databaseswouldbewelcomed.
Someimportantquestionshavebeenaddressedinthisthesisbutothersstillremain.For
comorbidities, this study documented broadly that gout patients have higher risk of









whetherallopurinoldecreases the riskofkidneystones ingoutpatientshasnotbeen
examined.Also,uricosuricagents increasekidneyexcretionofurateand theoretically
should increasetheriskofurolithiasisbutthere isnofirmevidenceregardingULTand
urolithiasis. Although allopurinol was found to have a neutral effect on all ?cause
mortality,whethertherelativecompositionofthecausesofmortalitychangesafterthe
useofULTingoutpatientsisunknown.
There are several strengths to thework in this thesis. Firstly, this thesis used large
databases thatarerepresentativeof thegeneralpopulationof theUKandTaiwan,so
selectionbias iscontrolledtoaminimum.Secondly,thedatasourcesarerecordedby
general practitioners directly and therefore the results derived reflect the real ?world
medicalpractice.Theadviceand recommendations that follow from thestudy results
could be readily implemented in the first ?line care of gout patients. Thirdly, the
















NHIRD containingdata from theentirepopulationofTaiwan,onlydata in theperiod
between 1995 and 2010 are available. The CPRD is limited by the mobility of the
participating patientswho canmove in and out of registered practices thus limiting
availabledatatoperiodsofactiveregistration.Theestimatesofprevalenceandincidence
of both databases therefore are period estimates, rather than life time estimates.
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